US20020177558A1 - Method of treating, preventing or inhibiting central nervous system injuries and diseases - Google Patents
Method of treating, preventing or inhibiting central nervous system injuries and diseases Download PDFInfo
- Publication number
- US20020177558A1 US20020177558A1 US09/839,905 US83990501A US2002177558A1 US 20020177558 A1 US20020177558 A1 US 20020177558A1 US 83990501 A US83990501 A US 83990501A US 2002177558 A1 US2002177558 A1 US 2002177558A1
- Authority
- US
- United States
- Prior art keywords
- lipoic acid
- subject
- composition
- disease
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 62
- 210000003169 central nervous system Anatomy 0.000 title claims abstract description 60
- 230000002401 inhibitory effect Effects 0.000 title claims description 9
- 208000001738 Nervous System Trauma Diseases 0.000 title claims 11
- 208000012902 Nervous system disease Diseases 0.000 title claims 9
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 117
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical class OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims abstract description 112
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 107
- -1 lipoic acid compound Chemical class 0.000 claims abstract description 75
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 claims abstract description 44
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 35
- 208000030886 Traumatic Brain injury Diseases 0.000 claims abstract description 21
- 230000009529 traumatic brain injury Effects 0.000 claims abstract description 21
- 206010029350 Neurotoxicity Diseases 0.000 claims abstract description 19
- 206010044221 Toxic encephalopathy Diseases 0.000 claims abstract description 19
- 230000007135 neurotoxicity Effects 0.000 claims abstract description 19
- 231100000228 neurotoxicity Toxicity 0.000 claims abstract description 19
- 206010036312 Post-traumatic epilepsy Diseases 0.000 claims abstract description 18
- 229910052742 iron Inorganic materials 0.000 claims abstract description 18
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 14
- 208000026139 Memory disease Diseases 0.000 claims abstract description 12
- 230000002829 reductive effect Effects 0.000 claims abstract description 12
- 206010027175 memory impairment Diseases 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- DMEKUKDWAIXWSL-UHFFFAOYSA-N n,n-dimethyl-7-nitro-9h-fluoren-2-amine Chemical compound [O-][N+](=O)C1=CC=C2C3=CC=C(N(C)C)C=C3CC2=C1 DMEKUKDWAIXWSL-UHFFFAOYSA-N 0.000 claims abstract description 10
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims abstract description 10
- 201000006474 Brain Ischemia Diseases 0.000 claims abstract description 9
- 206010008120 Cerebral ischaemia Diseases 0.000 claims abstract description 9
- 208000006011 Stroke Diseases 0.000 claims abstract description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 9
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 9
- 239000001301 oxygen Substances 0.000 claims abstract description 9
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 9
- 239000003430 antimalarial agent Substances 0.000 claims abstract description 8
- 201000004792 malaria Diseases 0.000 claims abstract description 8
- 210000005036 nerve Anatomy 0.000 claims abstract description 8
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims abstract description 7
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 7
- 231100000816 toxic dose Toxicity 0.000 claims abstract description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 43
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 33
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 32
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 30
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical group COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 25
- 235000019165 vitamin E Nutrition 0.000 claims description 22
- 239000011709 vitamin E Substances 0.000 claims description 22
- 229930003427 Vitamin E Natural products 0.000 claims description 21
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 21
- 229940046009 vitamin E Drugs 0.000 claims description 21
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 19
- 239000012530 fluid Substances 0.000 claims description 19
- 239000002516 radical scavenger Substances 0.000 claims description 19
- 229960003180 glutathione Drugs 0.000 claims description 18
- 238000009527 percussion Methods 0.000 claims description 16
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 15
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 14
- 229940076788 pyruvate Drugs 0.000 claims description 14
- 235000019154 vitamin C Nutrition 0.000 claims description 14
- 239000011718 vitamin C Substances 0.000 claims description 14
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 13
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 13
- 229930003268 Vitamin C Natural products 0.000 claims description 13
- 229960003966 nicotinamide Drugs 0.000 claims description 13
- 235000005152 nicotinamide Nutrition 0.000 claims description 13
- 239000011570 nicotinamide Substances 0.000 claims description 13
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 12
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 12
- 229960003987 melatonin Drugs 0.000 claims description 12
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 11
- 229960004308 acetylcysteine Drugs 0.000 claims description 11
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 claims description 10
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000003900 neurotrophic factor Substances 0.000 claims description 6
- 238000002633 shock therapy Methods 0.000 claims description 6
- 230000003116 impacting effect Effects 0.000 claims description 5
- 206010073306 Exposure to radiation Diseases 0.000 claims description 3
- 208000028412 nervous system injury Diseases 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 2
- 208000014674 injury Diseases 0.000 abstract description 58
- 230000006378 damage Effects 0.000 abstract description 57
- 208000027418 Wounds and injury Diseases 0.000 abstract description 50
- 206010010904 Convulsion Diseases 0.000 abstract description 34
- 238000011282 treatment Methods 0.000 abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 18
- 201000010099 disease Diseases 0.000 abstract description 17
- 210000004556 brain Anatomy 0.000 abstract description 13
- FUMFVZQFUSTSBW-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-5-(dithiolan-3-yl)pentanamide Chemical compound CN(C)CCNC(=O)CCCCC1CCSS1 FUMFVZQFUSTSBW-UHFFFAOYSA-N 0.000 abstract description 9
- 230000008733 trauma Effects 0.000 abstract description 8
- 230000005855 radiation Effects 0.000 abstract description 5
- 208000029028 brain injury Diseases 0.000 abstract description 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 2
- 208000023105 Huntington disease Diseases 0.000 abstract description 2
- 208000018737 Parkinson disease Diseases 0.000 abstract description 2
- 208000017004 dementia pugilistica Diseases 0.000 abstract description 2
- SHMXLCRUTGTGGS-UHFFFAOYSA-N dithiolane-3-carboxylic acid Chemical compound OC(=O)C1CCSS1 SHMXLCRUTGTGGS-UHFFFAOYSA-N 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 45
- 238000007920 subcutaneous administration Methods 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 20
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 20
- 238000002347 injection Methods 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 17
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 17
- 230000000324 neuroprotective effect Effects 0.000 description 16
- 239000000523 sample Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 210000002569 neuron Anatomy 0.000 description 14
- 150000003254 radicals Chemical class 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 239000003963 antioxidant agent Substances 0.000 description 11
- 238000007912 intraperitoneal administration Methods 0.000 description 11
- 210000003625 skull Anatomy 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 229940087168 alpha tocopherol Drugs 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 10
- 229960000984 tocofersolan Drugs 0.000 description 10
- 235000004835 α-tocopherol Nutrition 0.000 description 10
- 239000002076 α-tocopherol Substances 0.000 description 10
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 9
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 206010002091 Anaesthesia Diseases 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- 230000037005 anaesthesia Effects 0.000 description 8
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 208000028867 ischemia Diseases 0.000 description 8
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical class NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 8
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 108010054147 Hemoglobins Proteins 0.000 description 7
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 7
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 7
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 7
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000015654 memory Effects 0.000 description 7
- 230000004112 neuroprotection Effects 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 7
- 230000000007 visual effect Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 102000015336 Nerve Growth Factor Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 6
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 6
- 230000000589 amygdalar effect Effects 0.000 description 6
- 229930195712 glutamate Natural products 0.000 description 6
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 6
- 229960003132 halothane Drugs 0.000 description 6
- 210000003128 head Anatomy 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 229940053128 nerve growth factor Drugs 0.000 description 6
- 230000002887 neurotoxic effect Effects 0.000 description 6
- 210000004761 scalp Anatomy 0.000 description 6
- 229910052711 selenium Inorganic materials 0.000 description 6
- 239000011669 selenium Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000007954 hypoxia Effects 0.000 description 5
- 230000000598 lipoate effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 231100000189 neurotoxic Toxicity 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 238000000134 MTT assay Methods 0.000 description 4
- 231100000002 MTT assay Toxicity 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000000971 hippocampal effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000013016 learning Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 3
- 241001269524 Dura Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229940123457 Free radical scavenger Drugs 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 208000028361 Penetrating Head injury Diseases 0.000 description 3
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000003570 air Substances 0.000 description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 3
- 210000004727 amygdala Anatomy 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 238000011278 co-treatment Methods 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000001314 paroxysmal effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 210000004129 prosencephalon Anatomy 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 230000001020 rhythmical effect Effects 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- 206010001526 Air embolism Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 208000034693 Laceration Diseases 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 description 2
- 108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GRXKLBBBQUKJJZ-UHFFFAOYSA-N Soman Chemical compound CC(C)(C)C(C)OP(C)(F)=O GRXKLBBBQUKJJZ-UHFFFAOYSA-N 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 230000006851 antioxidant defense Effects 0.000 description 2
- 201000007201 aphasia Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000009537 cortical lesion Effects 0.000 description 2
- 238000007428 craniotomy Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 210000001947 dentate gyrus Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000001709 ictal effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000037041 intracellular level Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000009520 penetrating brain damage Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000003617 peroxidasic effect Effects 0.000 description 2
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000006950 reactive oxygen species formation Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000011808 rodent model Methods 0.000 description 2
- 208000004003 siderosis Diseases 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 238000012421 spiking Methods 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- JWHRJXBYZRXHOR-RRDODSEGSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;(2s)-5-oxopyrrolidine-2-carboxylic acid;(2s)-pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1.OC(=O)[C@@H]1CCC(=O)N1.OC(=O)[C@@H](N)CC1=CNC=N1 JWHRJXBYZRXHOR-RRDODSEGSA-N 0.000 description 1
- YRRQUPZAYQSFEM-IHPZHDCMSA-N (2s)-2-aminopentanedioic acid;(2s)-5-oxopyrrolidine-2-carboxylic acid;(2s)-pyrrolidine-2-carboxamide Chemical compound NC(=O)[C@@H]1CCCN1.OC(=O)[C@@H]1CCC(=O)N1.OC(=O)[C@@H](N)CCC(O)=O YRRQUPZAYQSFEM-IHPZHDCMSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical class OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010052346 Brain contusion Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010053398 Clonic convulsion Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010254 Concussion Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011951 Decompression Sickness Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000000202 Diffuse Axonal Injury Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 102400000242 Dynorphin A(1-17) Human genes 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LHPJANNUQBDRNT-UHFFFAOYSA-N N-(azulen-1-ylmethylidene)hydroxylamine Chemical class C1=CC=CC=C2C(C=NO)=CC=C21 LHPJANNUQBDRNT-UHFFFAOYSA-N 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000027626 Neurocognitive disease Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 102100029268 Neurotrophin-3 Human genes 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 241000238633 Odonata Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000033952 Paralysis flaccid Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 description 1
- 102000004892 Pyroglutamyl-peptidase II Human genes 0.000 description 1
- 108090001002 Pyroglutamyl-peptidase II Proteins 0.000 description 1
- DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 1
- 241000219289 Silene Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004830 Super Glue Substances 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000006993 Weiss annulation reaction Methods 0.000 description 1
- NDDAQHROMJDMKS-XFYXLWKMSA-N [(2s,3s,5s,8r,9s,10s,13s,14s)-2-hydroxy-10,13-dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl]azanium;chloride Chemical compound Cl.C1[C@H](N)[C@@H](O)C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 NDDAQHROMJDMKS-XFYXLWKMSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000004716 alpha keto acids Chemical class 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004164 analytical calibration Methods 0.000 description 1
- 239000003994 anesthetic gas Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- NLYNIRQVMRLPIQ-XQLAAWPRSA-N artemotil Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OCC)O[C@H]4[C@]32OO[C@@]1(C)O4 NLYNIRQVMRLPIQ-XQLAAWPRSA-N 0.000 description 1
- 229960002970 artemotil Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003935 attention Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 231100000871 behavioral problem Toxicity 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 1
- 229960001590 butorphanol tartrate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000013172 carotid endarterectomy Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000020930 dietary requirements Nutrition 0.000 description 1
- 230000009521 diffuse axonal injury Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- XLZOVRYBVCMCGL-BPNVQINPSA-L disodium;4-[(z)-[tert-butyl(oxido)azaniumylidene]methyl]benzene-1,3-disulfonate Chemical compound [Na+].[Na+].CC(C)(C)[N+](\[O-])=C\C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O XLZOVRYBVCMCGL-BPNVQINPSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 210000005110 dorsal hippocampus Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001787 epileptiform Effects 0.000 description 1
- FGBJXOREULPLGL-UHFFFAOYSA-N ethyl cyanoacrylate Chemical compound CCOC(=O)C(=C)C#N FGBJXOREULPLGL-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 229910001448 ferrous ion Inorganic materials 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 208000028331 flaccid paralysis Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 206010019465 hemiparesis Diseases 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000004694 hippocampus damage Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 210000004283 incisor Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 108010020410 methionine sulfoxide reductase Proteins 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- UEDWDOQXHOTTRB-WQLSENKSSA-N n-tert-butyl-1-(2-sulfophenyl)methanimine oxide Chemical compound CC(C)(C)[N+](\[O-])=C\C1=CC=CC=C1S(O)(=O)=O UEDWDOQXHOTTRB-WQLSENKSSA-N 0.000 description 1
- IYSYLWYGCWTJSG-UHFFFAOYSA-N n-tert-butyl-1-phenylmethanimine oxide Chemical compound CC(C)(C)[N+]([O-])=CC1=CC=CC=C1 IYSYLWYGCWTJSG-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000006776 neuronal homeostasis Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 210000000103 occipital bone Anatomy 0.000 description 1
- 230000031868 operant conditioning Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940097156 peroxyl Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 108010012938 polyethylene glycol-superoxide dismutase Proteins 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003045 protirelin derivative Substances 0.000 description 1
- 229960003351 prussian blue Drugs 0.000 description 1
- 239000013225 prussian blue Substances 0.000 description 1
- 239000007845 reactive nitrogen species Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000003568 synaptosome Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 210000000966 temporal muscle Anatomy 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to a method of treating, preventing or inhibiting central nervous system (CNS) injuries and diseases.
- CNS central nervous system
- the invention relates to a method of treating, preventing or inhibiting a CNS injury or disease in a subject by the administration of at least one lipoic acid compound to the subject.
- Traumatic brain injury can initiate a cascade of events which may lead to dramatic elevation of intracranial pressure (ICP), cerebral edema, ischemia, intracranial hemorrhage and dysfunction of cerebrovascular regulatory mechanisms essential for survival.
- ICP intracranial pressure
- cerebral edema cerebral edema
- ischemia cerebral edema
- intracranial hemorrhage and dysfunction of cerebrovascular regulatory mechanisms essential for survival.
- Deficits in memory, attention, and perception, emotional disorders, social behavioral problems, seizures (including non-convulsive seizures), paralysis, aphasia, post-traumatic epilepsy (PTE), and oxidative stress-induced neurotoxicity may result from TBI.
- Penetrating brain injuries associated with retained intracranial ferric metal fragments and inevitably associated with hemorrhage, are highly likely to produce posttraumatic epilepsy (PTE). See Salazar, A. M., et al., (1985) Neurology 35:1406-1414. Development of seizures following penetrating craniocerebral trauma has been associated with the presence of hematoma, total brain volume loss, presence of retained metal fragments, hemiparesis, aphasia, visual field loss, organic mental disorder, headache and a history of seizures during the first year post injury.
- ROS neurotoxic reactive oxygen species
- ROS central nervous system
- R carbon-centered radicals
- R-HC-R carbon-centered radicals
- Scavengers such as vitamin E, also known as alpha-tocopherol, donate a hydrogen atom to a radical, thereby becoming a secondary radical. Since the tocopherol radical is rather stable, it breaks the chain reaction, hence these scavengers are known as “chain-breaking antioxidants”.
- the several neurotoxic pathways can produce a variety of small, diffusible ROS, including superoxide, nitric oxide, peroxyl, perhydroxyl, peroxynitrite, hypochlorous and singlet oxygen.
- the antioxidant enzyme superoxide dismutase converts the superoxide radical to hydrogen peroxide, a non-radical oxidizing agent that can engage in a number of iron-catalyzed reactions producing the very toxic hydroxyl ion.
- the ferrous ion can trigger the Fenton reaction with hydrogen peroxide to form hydroxyl ions plus a ferric ion.
- Iron ions can also catalyze the Haber-Weiss reaction, in which superoxide and hydrogen peroxide react to form hydroxyl ions and molecular oxygen. Superoxide can also react with nitric oxide to produce the intermediate peroxynitrite, which subsequently yields the hydroxyl radical.
- GSH glutathione
- ALA alpha-lipoic acid
- DHLA dihydrolipoic acid
- coenzyme Q vitamin E
- vitamin C vitamin C
- pyruvate pyruvate
- melatonin niacinamide
- niacinamide niacinamide
- TirilazadTM Upjohn
- Peg-SOD superoxide dimutase linked to polyethylene glycol
- TirilazadTM is an antioxidant aminosteroid which proved to be clinically unsuccessful against stroke because it did not readily cross the blood brain barrier and it failed to protect the hippocampus.
- a number of large clinical trials have failed to demonstrate a benefit of administering phenytoin, phenobarbital, carbamazepine or valproate as a way to prevent the onset of PTE.
- the present invention relates to a method of treating a subject suffering from a CNS injury or disease comprising administering to the subject a composition comprising a therapeutically effective amount of at least one lipoic acid compound.
- the present invention relates to a method of preventing or inhibiting a CNS injury or disease in a subject comprising administering to the subject a composition comprising a therapeutically effective amount of at least one lipoic acid compound.
- the invention relates to a method of preventing, inhibiting or treating neurotoxicity or memory deficit in a subject comprising administering to the subject a composition comprising a therapeutically effective amount of at least one lipoic acid compound.
- the composition may be administered before the electroconvulsive shock therapy to mitigate memory loss.
- the CNS injury or disease may be traumatic brain injury (TBI), posttraumatic epilepsy (PTE), stroke, cerebral ischemia, or a neurodegenerative disease.
- CNS injury may be induced by fluid percussion, a blunt object impacting the head of the subject, an object which penetrates the head of the subject, or exposure to radiation, ionizing or iron plasma, a nerve agent, cyanide, toxic concentrations of oxygen, CNS malaria, or an anti-malaria agent.
- the lipoic acid compound may be alpha-lipoic acid (ALA), dihydrolipoic acid (DHLA or DHL), 2-(N,N-dimethylamine) ethylamido lipoate-HCL (LA-plus), the oxidized or reduced R- or S-isomers, a metabolite of ⁇ -lipoic acid, or an analog thereof.
- the lipoic acid compound is ALA, DHLA, or LA-plus.
- the composition may further comprise at least one ROS scavenger.
- ROS scavengers include coenzyme Q, vitamin E, vitamin C, pyruvate, melatonin, niacinamide, N-acetylcysteine, GSH, and nitrones.
- the therapeutically effective amount of the lipoic acid compound administered to the subject is about 0.001 mg to about 20 mg per kg of the subject, preferably about 1 mg to about 10 mg per kg of the subject, more preferably about 3 mg to about 10 mg per kg of the subject.
- the total daily amount of the lipoic acid compound administered to the subject is about 50 mg to about 1200 mg, preferably about 100 mg to about 1000 mg, more preferably about 200 mg to about 800 mg, even more preferably about 300 mg to about 600 mg.
- the invention relates to administering the lipoic acid compound to a subject a period of time before the subject is exposed or likely to be exposed to a risk of CNS injury or damage or before the subject is exposed to conditions likely to cause neurotoxicity or memory deficit or both.
- the conditions likely to cause CNS injury or damage, neurotoxicity or memory deficit include electroconvulsive shock therapy, traumatic brain injury (TBI), posttraumatic epilepsy (PTE), stroke, cerebral ischemia, neurodegenerative diseases, fluid percussion, a blunt object impacting the head of the subject, an object penetrating the head of the subject, radiation, ionizing or iron plasma, nerve agents, cyanide, toxic concentrations of oxygen, CNS malaria, and anti-malaria agents.
- CNS injury or damage Other conditions likely to cause CNS injury or damage, neurotoxicity or memory deficit include certain medical procedures or conditions associated with risk for CNS ischemia, hypoxia or embolism such as brain tumor, brain surgery, open heart surgery, carotid endarterectomy, repair of aortic aneurysm, atrial fibrillation, cardiac arrest, cardiac or other catheterization, phlebitis, thrombosis, prolonged bed rest, prolonged stasis (such as during space travel or long trips via airplane, rail, car or other transportation), CNS injury secondary to air/gas embolism or decompression sickness.
- hypoxia or embolism such as brain tumor, brain surgery, open heart surgery, carotid endarterectomy, repair of aortic aneurysm, atrial fibrillation, cardiac arrest, cardiac or other catheterization, phlebitis, thrombosis, prolonged bed rest, prolonged stasis (such as during space travel or long trips via airplane, rail, car or other transportation), CNS injury secondary to air/gas embo
- the period of time may be about 72 hours to about the time of expected exposure, preferably about 48 hours to about the time of expected exposure, more preferably about 12 hours to about the time of expected exposure, even more preferably about 4 hours to about the time of expected exposure, and most preferably about 2 hours to about the time of expected exposure.
- the administration of the lipoic acid compound may be continuous from the initial time of treatment to the end of treatment.
- a transdermal patch or a slow-release formulation may be used to continually administer the lipoic acid compound to the subject for a given period of time.
- the lipoic acid compound may be administered to the subject periodically.
- the lipoic acid compound may be first administered at about 24 hours before the time of expected exposure and then administered at about every 2 hours thereafter.
- At least one ROS scavenger such as coenzyme Q, vitamin E, vitamin C, pyruvate, melatonin, niacinamide, N-acetylcysteine, GSH, or a nitrone, is administered prophylactically in combination with the prophylactic administration of the lipoic acid compound.
- the composition may further comprise a pharmaceutically acceptable excipient.
- the composition may be administered intravenously, intradermally, subcutaneously, orally, transdermally, transmucosally or rectally.
- the composition is orally administered.
- the invention relates to a pharmaceutical composition for treating or preventing CNS injury, disease or neurotoxicity in a subject comprising a therapeutically effective amount of at least one lipoic acid compound and a pharmaceutically acceptable excipient.
- the lipoic acid compound may be ALA, DHLA, LA-plus, the oxidized or reduced R- or S-isomers, a metabolite of ALA, or an analog thereof.
- the pharmaceutical composition may further comprise at least one ROS scavenger. Examples of suitable ROS scavengers include coenzyme Q, vitamin E, vitamin C, pyruvate, melatonin, niacinamide, N-acetylcysteine, GSH, and nitrones.
- the invention relates to a kit comprising a composition comprising a therapeutically effective amount of at least one lipoic acid compound.
- the lipoic acid compound may be ALA, DHLA, LA-plus, the oxidized or reduced R- or S-isomers, a metabolite of ALA, or an analog thereof.
- the lipoic acid compound is ALA, DHLA, or LA-plus.
- the kit or the composition may further comprise at least one ROS scavenger.
- Suitable ROS scavengers include coenzyme Q, vitamin E, vitamin C, pyruvate, melatonin, niacinamide, N-acetylcysteine, GSH, and nitrones.
- the kit may further comprise a device for administering the composition to a subject such as an injection needle, an inhaler, a transdermal patch.
- the kit may also comprise instructions for use.
- FIG. 1 illustrates that DHLA is protective in a concentration-related manner against hemoglobin-induced toxicity in cultured neurons in vitro.
- FIG. 2 illustrates that DHLA is protective against experimental spinal cord injury in rats in vivo.
- FIG. 3 a is an example of an iron-induced paroxysmal spiking seizure on electroencephalogram (EEG) in rat.
- FIG. 3 b is an example of an iron-induced spike-and-wave seizure on electroencephalogram (EEG) in rat.
- FIG. 4 illustrates that pretreatment with ALA and co-treatment with DHLA reduces iron chloride-induced seizure activity by about 55%.
- FIG. 5 illustrates the neuroprotective effects of DHL and SPBN.
- FIG. 6 illustrates the neuroprotective effects of DHL and PBN.
- the present invention relates to a method of preventing, treating, or both preventing and treating a CNS injury or disease by the administration of at least one lipoic acid compound.
- CNS injuries or disease include TBI, stroke, concussion (including post-concussion syndrome), cerebral ischemia, neurodegenerative diseases of the brain such as Parkinson's disease, Dementia Pugilistica, Huntington's disease and Alzheimer's disease, brain injuries secondary to seizures which are induced by radiation, exposure to ionizing or iron plasma, nerve agents, cyanide, toxic concentrations of oxygen, neurotoxicity due to CNS malaria or treatment with anti-malaria agents, and other CNS traumas.
- TBI TBI
- stroke concussion (including post-concussion syndrome)
- cerebral ischemia neurodegenerative diseases of the brain such as Parkinson's disease, Dementia Pugilistica, Huntington's disease and Alzheimer's disease
- brain injuries secondary to seizures which are induced by radiation, exposure to ionizing or iron plasma, nerve agents, cyanide, toxic concentrations of oxygen, neurotoxicity due to CNS malaria or treatment with anti-malaria agents, and other CNS traumas.
- lipoic acid compounds examples include alpha-lipoic acid (ALA), dihydrolipoic acid (DHLA or DHL), 2-(N,N-dimethylamine) ethylamido lipoate-HCL (LA-plus), the oxidized or reduced R- or S-isomers, the metabolites of ALA such as 6,8-bisnorlipoic acid and tetranorlipoic acid and analogs thereof.
- Analogs of lipoic acid compounds include lipoamides.
- ALA is a physiological constituent of mitochondrial membranes and is an essential cofactor in the oxidative decarboxylation of alpha-keto acids such as pyruvate and alpha-ketoglutarate.
- ALA is present in food and in mammalian tissues.
- ALA is clinically safe, well-tolerated and is currently used to treat peripheral neuropathy in patients with diabetes.
- ALA is stable in tablet form, can be given orally, has good bioavailability in humans, is well-tolerated and is endogenously converted to DHLA.
- Both ALA and DHLA are effective scavengers of numerous ROS and have been shown to be neuroprotective in several rodent models of cerebral ischemia. They are rapidly distributed to the central nervous system, improve memory, are active in both lipid and aqueous phases, and increase intracellular levels of GSH and ATP.
- ALA and DHLA may be used in methods for treating or prevention TBI, PTE and other CNS traumas.
- they protect neurons, among other things, by (1) acting as direct chain-breaking antioxidants; (2) recycling the antioxidant vitamins C and E; (3) scavenging at least 8 types of free radicals; (4) chelating decompartmentalized iron ions; (5) chelating copper ions; (6) increasing intracellular energy stores which include ATP; (7) regenerating and increasing intracellular levels of the endogenous antioxidant, glutathione; (8) increasing the ratio of reduced to oxidized coenzyme Q; and (9) providing methionine sulfoxide reductase with reducing equivalents.
- DHLA also enhances the repair of oxidatively damaged proteins.
- DHLA was recently demonstrated to be protective in a concentration-related manner (about 0.3 to about 10 micromolar) against hemoglobin-induced toxicity in cultured neurons in vitro.
- a concentration-related manner about 0.3 to about 10 micromolar
- Neurosci. Abs., 25, which is herein incorporated by reference.
- primary cultures of neurons derived from the forebrains of E-15 rat fetuses were pre-incubated with DHLA at several different concentrations for about 4 hours. The neurons were then exposed to about 10 micromoles of hemoglobin and resulted in about 50% viability after about a 24 hour exposure. Neuronal viability was assessed by using the colorimetric MTT assay of succinate dehydrogenase activity.
- MTT is a colorimetric dye, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, and is available from Sigma. Neuroprotection increased with increasing concentrations of DHLA. There was no evidence of neuroprotection where DHLA was coapplied with hemoglobin.
- DHLA was also demonstrated to be protective against experimental spinal cord injury in rats in vivo.
- about 5 micromoles of DHLA was administered intrathecally as a 2 hour pretreatment. Flaccid paralysis was acutely evident about 10 minutes after injection with dynorphin A and where there was no pretreatment with DHLA or co-treatment with DHLA.
- Pretreatment with DHLA and treatment after injury with DHLA was observed to improve motor scores. See Long et al., (1999) Neurosci. Abs. 25, which is herein incorporated reference.
- a modified Willmore model of ferric chloride-induced epilepsy may be used to automatically record and quantify seizure activity on a 24 hour basis as shown in FIGS. 3 a and 3 b.
- ferric chloride was injected into the cerebral cortex of a rat which elicits intense seizures.
- FIG. 3 a shows an example of an electroencephalograph (EEG) paroxysmal spiking seizure pattern.
- FIG. 3 b shows an example of an EEG “spike and wave” seizure pattern.
- LA-plus is a positively charged water soluble lipoic acid amide analog which shows a higher rate of intracellular reduction and retention than is seen with ALA, as well as better in vitro protection against glutamate-induced loss of GSH, formation of peroxide and neurotoxicity in cultured mouse hippocampal HT4 cells. See Tirosh et al., (1999) Free Rad. Biol & Med. 26(11/12):1418-1426, which is herein incorporated by reference.
- at least one ROS scavenger may also be administered.
- ROS scavengers include coenzyme Q, vitamin E, vitamin C, pyruvate, melatonin, niacinamide, N-acetylcysteine, GSH and nitrones.
- the neuroprotective efficacy of the lipoates may be enhanced by supplementary compounds.
- the neuroprotective efficacy of the lipoates might be enhanced by (1) combination with other free radical scavenger with slightly differing mechanisms of action (e.g. coenzyme Q; or nitrones); or (2) with other classes of neuroprotectants with fundamentally different mechanisms, such as the neurotrophic factors brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophins (e.g. NT-3) and/or the neuroprotective endogenous TRH analog, pyroGlu-Glu-Pro (known by its abbreviation, EEP).
- BDNF brain-derived neurotrophic factor
- NMF nerve growth factor
- NT-3 neurotrophins
- EEP neuroprotective endogenous TRH analog
- EEP neuroprotective endogenous TRH analog
- Coenzyme Q10 also known as ubiquinone
- CoQ10 levels in spinal cord have been reported to be decreased following injury and the changes were found to be reflective of the degree of trauma.
- Ubiquinone 10 has been found to be a lipid-soluble antioxidant which can prevent lipid peroxidation in brain synaptosomes and mitochondria, recycle vitamin E and scavenge ROS.
- Pretreatment with coenzyme Q reduced 33 malonate-induced neurotoxicity in vivo. See Beal et al., (1994) Eur. J. Pharmacology-Molec. Pharm.
- Nitrone-based free radical traps such as alpha-Phenyl-N-tert-butylnitrone (PBN), N-tert-Butyl- ⁇ -(2-sulfophenyl)nitrone (SPBN), Azulenyl nitrones, and NXY-059, offer a ROS scavenging mechanism which differs from vitamin E, the lipoic acids and other endogenous compounds.
- the nitrones react covalently with ROS to form stable nitroxides.
- nitrones may be co-administered with the lipoic acids of the invention.
- SPBN is an effective neuroprotectant without significant toxicity.
- the free radical scavenger SPBN is synergistic with brain-derived neurotrophic factor (BDNF) in survival of axotomized retinal ganglion cells.
- BDNF brain-derived neurotrophic factor
- PBN is a nitrone which has been shown to be neuroprotective in animal models of ischemia, even when administered post injury. PBN is also effective as a pre-treatment against DFP-induced convulsions.
- nitrones may be co-administered with lipoic acids to provide a synergistic neuroprotective effect.
- the times and amounts that the lipoic acid compounds and the supplementary compounds are administered may be varied.
- an individual known to be at risk for certain injuries may be administered a lipoate.
- the individual After an injury occurs, the individual would be administered a supplementary active compound such as a nitrone, trophin, or other free radical scavenger.
- the lipoate administered before the injury would confer a protection at the time of injury and afterwards.
- the post-injury administration of the supplementary active compound would provide a synergistic neuroprotective effect with the lipoate.
- TRH thyrotropin releasing hormone
- Both EEP and TRH are found in the brain.
- TRH thyrotropin releasing hormone
- EEP is neuroprotective against Glutamate-induced neurotroxicity.
- TRH thyrotropin releasing hormone
- TRH thyrotropin releasing hormone
- TRH thyrotropin releasing hormone
- Vitamin E alpha-Tocopherol
- Vitamin E is a normal dietary component and prevents peroxidative injury of sulfhydryl groups of glycolipids and glycoproteins by augmenting the antioxidant effects of enzyme systems such as glutathione peroxidase. It stimulates the synthesis of ATP, decreases lipid peroxidation, attenuates neurotoxic effects of iron in vitro, and prevents iron-induced seizures in vivo.
- enzyme systems such as glutathione peroxidase. It stimulates the synthesis of ATP, decreases lipid peroxidation, attenuates neurotoxic effects of iron in vitro, and prevents iron-induced seizures in vivo.
- vitamin E exhibits a slow rate of absorption through the blood brain barrier and is not suitable in methods to rapidly treat a brain injury, vitamin E may be suitable for prophylactic treatments and treatments over long periods of time.
- the lipoic acid compounds of the present invention may be coupled via an amide linkage to one of the three enzymes of the pyruvate dehydrogenase complex.
- a therapeutically effective amount of at least one lipoic acid compound or an analog thereof may be given prophylactically to a subject having a high risk for obtaining a CNS injury or disease.
- a subject pretreated with a lipoic acid compound or analog thereof would have an increased antioxidant reserve and would therefore have an increased resistance to CNS injuries and diseases.
- Administration of the lipoic acid compound may be continued after obtaining the CNS injury or disease.
- Lipoic acid compounds may be administered to a subject as a method of preventing or treating CNS damage induced by exposure to nerve agents such as Soman, sarin, VX and the like. Soman elicits a sustained increase in extracellular glutamate levels in the amygdala, induces the de-compartmentalization of iron in brain tissue and catalyzes the formation of ROS.
- nerve agents such as Soman, sarin, VX and the like. Soman elicits a sustained increase in extracellular glutamate levels in the amygdala, induces the de-compartmentalization of iron in brain tissue and catalyzes the formation of ROS.
- Lipoic acid compounds may be administered to a subject as a method of preventing or treating radiation-induced CNS damage as inhibition of free radical formation provides neuroprotection to cultured cortical neurons exposed to ionizing radiation and injections of lipoic acid protects hematopoietic tissues in gamma-irradiated mice. Lipoic acid should also protect against injury to CNS, cardiac and hematopoeitic tissues secondary to cancer chemotherapy.
- lipoic acid compounds may be administered to a subject suffering from CNS malaria or a subject being treated with Arteether and related antimalarial compounds as a method to prevent or treat CNS damage.
- the lipoic acid compounds may be administered to a subject exposed to high oxygen under pressure (OHP) as the pathophysiological mechanism in toxicity induced by OHP may involve free radical generation.
- OHP causes seizures and convulsions.
- the lipoic acid compounds may be administered prophylactically to a subject at risk for CNS injury or disease.
- Subjects at risk for CNS injury or disease include participants in contact sports such as football and boxing, military personnel, astronauts and others at risk for exposure to blast overpressure, blunt head trauma, and penetrating brain injury.
- the lipoic acid compounds may be administered intravenously, intradermally, subcutaneously, orally, transdermally, transmucosally or rectally.
- a therapeutically effective amount of the lipoic acid compound of the invention may be administered to a subject a period of time before the subject is exposed to a risk of CNS injury or damage or before the subject is exposed or likely to be exposed to conditions likely to cause neurotoxicity or memory deficit or both.
- the conditions likely to cause CNS injury or damage, neurotoxicity or memory deficit include electroconvulsive shock therapy, traumatic brain injury (TBI), posttraumatic epilepsy (PTE), stroke, cerebral ischemia, neurodegenerative diseases, fluid percussion, a blunt object impacting the head of the subject, an object penetrating the head of the subject, radiation, ionizing or iron plasma, nerve agents, cyanide, toxic concentrations of oxygen, CNS malaria, and anti-malaria agents.
- the period of time may be about 72 hours to about the time of expected exposure, preferably about 48 hours to about the time of expected exposure, more preferably about 12 hours to about the time of expected exposure, even more preferably about 4 hours to about the time of expected exposure, and most preferably about 2 hours to about the time of expected exposure. It is to be understood, however, that the lipoic acid compound may be administered at a period of time which is more than about 72 hours before the time of expected exposure. For example, the period of time may be about 7 days before the expected exposure.
- the administration of the lipoic acid compound may be continuous from the initial time of treatment to the end of treatment.
- a transdermal patch or a slow-release formulation may be used to continually administer the lipoic acid compound to the subject for a given period of time.
- the lipoic acid compound may be administered to the subject periodically. For example, the lipoic acid compound may be first administered at about 24 hours before the time of expected exposure and then administered at about every 2 hours thereafter.
- ROS scavengers such as coenzyme Q, vitamin E, vitamin C, pyruvate, melatonin, niacinamide, N-acetylcysteine, GSH, and nitrones may also be administered prophylactically along with the lipoic acid compound.
- a lipoic acid compound such as BDNF, nerve growth factor (NGF), neurotrophins, and analogs thereof, may be administered prophylactically along with the lipoic acid compound.
- the therapeutically effective amount of the lipoic acid compound administered prophylactically to the subject may be about 0.001 mg to about 20 mg per kg of the subject, preferably about 1 mg to about 10 mg per kg of the subject, more preferably about 3 mg to about 10 mg per kg of the subject.
- the total daily amount of the lipoic acid compound administered prophylactically to the subject may be about 50 mg to about 1200 mg, preferably about 100 mg to about 1000 mg, more preferably about 200 mg to about 800 mg, even more preferably about 300 mg to about 600 mg.
- the lipoic acid compounds of the invention may be incorporated into pharmaceutical compositions suitable for administration.
- Such compositions typically comprise at least one lipoic acid or at least one analog thereof and a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
- the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated.
- Supplementary active compounds such as ROS scavengers may also be incorporated into the compositions.
- Other supplementary active compounds include neurotrophic factors such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophins, and analogs thereof.
- a pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration.
- routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral, transdermal, transmucosal, and rectal administration.
- Solutions or suspensions used for parenteral, intradermal, or subcutaneous application may include a sterile diluent such as water for injection, a saline solution, a fixed oil, a polyethylene glycol, glycerine, propylene glycol or other synthetic solvent, an antibacterial agent such as benzyl alcohol or methyl paraben, an antioxidant such as ascorbic acid or sodium bisulfite, a chelating agent such as ethylenediaminetetraacetic acid, a buffer such as an acetate, citrate or phosphate and an agent for the adjustment of tonicity such as sodium chloride or dextrose. pH may be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. Parenteral preparations may be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- compositions suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
- the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier may be a solvent or dispersion medium containing water, ethanol, a polyol such as glycerol, propylene glycol, and liquid polyetheylene glycol, and the like, and suitable mixtures thereof.
- the proper fluidity may be maintained by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion or by the use of surfactants.
- Prevention of the action of microorganisms may be achieved by various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
- isotonic agents such as sugars, polyalcohols such as manitol, sorbitol, sodium chloride may be used in the composition.
- Prolonged absorption of the injectable compositions may be brought about by including an agent which delays absorption such as aluminum monostearate and gelatin.
- Sterile injectable solutions may be prepared by incorporating the lipoic acid compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the lipoic acid compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets.
- the lipoic acid compound may be incorporated with excipients and used in the form of tablets, troches, or capsules.
- Pharmaceutically compatible binding agents, adjuvants, or both may be included as part of the composition.
- the tablets, pills, capsules, troches and the like may contain a binder such as microcrystalline cellulose, gum tragacanth or gelatin, an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch, a lubricant such as magnesium stearate or Sterotes, a glidant such as colloidal silicon dioxide, a sweetening agent such as sucrose or saccharin, or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose
- a disintegrating agent such as alginic acid, Primogel, or corn starch
- a lubricant such as magnesium stearate or Sterotes
- a glidant such as colloidal silicon dioxide
- a sweetening agent such as sucrose or saccharin
- the compounds may be delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
- a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
- Systemic administration may also be by transmucosal or transdermal means.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
- Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
- the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
- the active compounds may be prepared with carriers which protect the lipoic acid compounds against rapid elimination from the body, such as a controlled release formulation, implants and microencapsulated delivery systems.
- a controlled release formulation implants and microencapsulated delivery systems.
- Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid may be used. Methods of preparing these formulations will be apparent to those skilled in the art.
- the materials may also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art.
- compositions may be formulated in dosage unit forms for ease of administration and uniformity of dosage.
- a dosage unit form refers to a physically discrete unit suitable for use as a unitary dosage for the subject to be treated. Each unit may contain a predetermined quantity of the lipoic acid compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the specification for the dosage unit form of the invention is dictated by and directly dependent on the unique characteristics of the particular lipoic acid compound and the particular therapeutic effect to be achieved.
- Toxicity and therapeutic efficacy of the particular lipoic acid compound may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
- Lipoic acid compound which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
- the data obtained from the cell culture assays and animal studies may be used in formulating a range of dosage for use in humans.
- the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
- IC50 i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms
- levels in plasma may be measured, for example, by high performance liquid chromatography.
- a therapeutically effective amount of the lipoic acid compound of the present invention ranges from about 0.001 mg to about 200 mg per kg of the subject, preferably about 25 mg to about 125 mg per kg of the subject, more preferably about 50 mg to about 100 mg per kg of the subject.
- the therapeutically effective amount ranges from about 0.001 mg to about 20 mg per kg of the human, preferably about 1 mg to about 10 mg per kg of the human, more preferably about 3 mg to about 10 mg per kg of the human.
- treatment of a subject with a therapeutically effective amount of a lipoic acid compound can include a single treatment or a series of treatments.
- Administration of the lipoic acid compound may be administered prophylactically before CNS trauma, in individuals at risk.
- the lipoic acid compound may be administered during and after CNS trauma. It is appreciated that the effective dosage of the lipoic acid compound may increase or decrease over the course of a particular treatment.
- NCM neuronal culture medium
- the cells are plated onto poly-L-lysine-coated 48 well plates at a density of 10 6 cells/ml.
- the cultures are treated with cytosine arabinoside (10 ⁇ 5 M) for 4 days. All cultures are maintained in an incubator comprising 5% CO 2 at 37° C. for about 6 days to about 15 days prior to use.
- Oxidative injury is assessed by using an MTT assay (Sigma, St. Louis, Mo.). About 24 h after exposure to either hemoglobin or an oxidative insult, MTT is added to each test well such that the final concentration of the dye is about 0.15 mg/ml. Plates are returned to the incubator for about 1 hr at which time unincorporated MTT is removed and the plates are allowed to air dry. The purple formazan product indicative of viable cells is then dissolved by adding about 250 ⁇ l of acidified isopropanol comprising about 95% isopropanol and about 5% 2N HCI. About 200 ⁇ l aliquots are collected and the absorbance of these aliquots are measured on an ELISA plate reader at about 540 nm. Control (untreated) wells are included in each experiment, and viability is calculated as the percentage of mean control values for each plate.
- MTT assay Sigma, St. Louis, Mo.
- the concentrations of ALA and LA-plus are about 25, about 50 and about 100 micromolar.
- the concentrations of selenium are about 10 and about 20 micromolar.
- the concentrations of pyruvate are about 0.3, about 1.0, and about 3.0 mM.
- the concentrations of SPBN ranges from about 1 to about 50 mM.
- rats are anesthetized with about 70 mg/kg of ketamine and about 6 mg/kg xylazine administered i.m. and the scalp is shaved.
- the anesthetized rat is then placed in a stereotaxic apparatus and a surgical scrub of the scalp is performed.
- the scalp is infiltrated with about 0.2 ml of a 1% lidocaine solution, a midline incision is made, and the scalp and temporal muscles are reflected.
- the rats After being retested in the visual discrimination task to ensure a return to presurgery levels of accuracy the rats are anesthetized with halothane and prepared with femoral vein and tail artery catheters in experiments employing secondary hypoxia. Under aseptic conditions, the vessels are exposed by blunt dissection and PE 50 catheters filled with a sterile heparinized saline, about 10 USP units/ml, are inserted and secured using 3-O nylon sutures. Patency of the i.v. cannulae is maintained with about 0.2 ml flushes with heparinized saline immediately following drug or vehicle injections.
- halothane anesthesia is maintained using compressed air and a continuous flow anesthesia system available from Stoelting (Wood Dale, Ill.) in combination with a Fluovac (Stoelting, Wood Dale, Ill.) halothane scavenger, which recaptures anesthetic gases by vacuum and thereby minimizes the escape of halothane to the ambient air.
- the resultant rapid injection of a small volume of saline into the closed cranial cavity causes a pulse of increased intracranial pressure that is associated with a brief deformation of brain tissue.
- the pressure pulse is measured extracranially by a pressure transducer, Model 211B4, available from Kistler Instruments Corp. (Amherst, N.Y.) and recorded on a digital storage oscilloscope, Tecktronix 2212, (Tektronix Beaverton, Oreg.) and based upon prior instrument calibration is expressed in atmospheres. Core temperature are maintained using a homeothermic blanket available from Harvard Apparatus (South Natick, Mass.). Temperature of the temporalis muscle is continuously monitored using a thermistor probe available from Physiotemp Systems (Clifton, N.J.). Halothane administration is maintained at about 1.0%.
- Arterial blood samples are removed immediately preceding and at about 30 minutes following sham treatments or fluid percussion injuries for analysis of blood gases, electrolytes, pH, lactic acid, and hematocrit.
- Fluid percussion pressures are about 4.0 to about 5.0 atm, and typically yield moderately severe brain injuries.
- Cranial luer connectors are disconnected immediately following delivery of the fluid percussion pulse. Sham control rats are handled in an identical manner with the exception of the delivery of the fluid pressure pulse.
- post-traumatic hypoxia is induced by substituting a 10% oxygen source to deliver the halothane for continued anesthesia.
- an arterial blood sample is removed for blood gas analysis.
- the arterial catheters are then removed and the surgical wound sites are closed with nylon sutures and treated with the topical antibacterial furizolidine.
- the rats are kept warm with a Vetko thermal barrier until recovered from anesthesia (i.e. ambulatory), at which time they are returned to the operant conditioning chambers or to their home cages.
- the surgical wound sites are closed with nylon sutures and treated with the topical antibacterial furizolidine.
- the dosages of the lipoic acid compounds may be adjusted based on evaluation of initial studies.
- ALA will be given s.c., as per Wolz & Kriglstein (1996) Neuropharmacology 35:369-375, which is herein incorporated by reference.
- about 50 mg/kg of ALA and about 25 mg/kg of DHLA is administered s.c. about 30 minutes after FP (immediately after the post-FP hypoxia).
- follow-up doses of about 100 mg/kg of ALA and about 50 mg/kg of DHLA may be given s.c. at about 3, about 24, about 48 and about 72 hours after FP.
- ALA is administered s.c. daily for three days prior to FP, followed by about 50 mg/kg s.c. one hour prior to FP.
- ALA is administered only, then about 100 mg/kg of ALA are administered s.c. about 72 hours, about 48 hours, about 24 hours, about 2 hours or a combination thereof prior to FP.
- coenzyme Q 10 is administered, then about 200 mg/kg of coenzyme Q 10 is administered p.o. ⁇ 10 days.
- SPBN is administered, about 300 mg/kg is administered s.c. q.i.d. during about 72 hours of pretreatment.
- alpha-tocopherol is administered, about 25 mg/kg is injected i.p. about two hours prior to FP.
- About 50 micrograms i.p. of selenium may be administered when alpha-tocopherol is administered.
- Sprague-Dawley rats weighing about 200 g to about 280 g from Charles River (Wilmington, Mass.) are maintained either in hanging cages or housed separately, on 12 hour light-dark cycles with unlimited access to food and water. All procedures are performed with aseptic techniques and sterile instruments and electrodes/cannulae which are autoclaved or glass bead sterilized. Surgical procedures are performed with about 37.5 mg/kg intraperitoneal injection i.p. pentobarbital sodium anesthesia. At the time of complete insensitivity to painful stimuli, e.g.
- the scalp is shaved, a surgical scrub is performed, and the rat placed in a stereotaxic frame.
- the incisor bar is set about 3.3 mm below the intraaural line. The skull is exposed and the periosteum removed and the surface of the skull is dried and marked for electrode placement.
- a burr hole is made in a location over the sensorimotor cortex, about 2 mm posterior and lateral to bregma and either 300 mM iron chloride or saline is unilaterally stereotaxically injected intracortically, 2.5 mm ventral to bregma, using a 30 gauge Hamilton syringe over a period of about 2 minutes. After the Hamilton syringe is withdrawn, gelfoam (Gelfoam, Kalamazoo, Mich.) is packed into the burr hole. Extradural cortical recording electrodes are implanted to evaluate the presence or absence of seizure events (rhythmic ictal EEG).
- Burr holes for the EEG leads from the transmitter, are drilled in the top of the skull, about 2 mm on either side of the midline and about 2 mm anterior to lambda.
- the silastic insulation on the EEG leads is removed to reveal about 5 to about 8 coils of the wire.
- the exposed wire is then turned about 180° in line with the remaining lead and placed sideways into the hole in the skull.
- the leads are then attached to the implanted electrodes with a lead connector kit or leads are continuous to the transmitter. All electrodes and leads are coated with TeflonTM except for contact points requiring conductance.
- a cannula may also then be placed in the right lateral ventricle if i.c.v. drug administration is planned. If an i.c.v.
- an acrylic mount is constructed to hold the cannula in place while dental acrylic is secured over set screws and the electrodes (opening around the electrodes and cannula is closed with gel foam). Otherwise, if no i.c.v. cannula is implanted, the electrode assembly is completely subcutaneous.
- a transmitter is inserted in the opening.
- a single channel transmitter such as CTAF40 (Data Sciences International, St. Paul, Minn.) is used for the acute seizure study;
- a two-channel transmitter such as TL10M3-F50-EET (Data Sciences International, St. Paul, Minn.), is used for bilateral hippocampal recording electrodes in the amygdalar delayed seizure study.
- a sterile trocar with sleeve will be used to create a subcutaneous channel opening up to the scalp incision, and, after the trocar is removed, the transmitters are passed through the sleeve to the appropriate burrholes in the skull surface making contact with the dura and then covered with gelfoam.
- a small acrylic mount is constructed to cover the electrodes and a set screw in the skull for stability of the recording electrodes.
- Burr holes are made in locations appropriate for stereotaxic coordinates per atlas of Paxinos and Watson, THE RAT BRAIN IN STEREOTAXIC COORDINATES. Academic Press, New York (1986), which is herein incorporated by reference. Coordinates for the amygdaloid body is about 3.3 mm posterior and about 5.0 mm lateral to the bregma and about 8.5 mm below the surface of the skull. A 22 gauge guide cannula, lumen occluded with stylet, is stereotaxically placed about 0.5 mm above the left amygdala.
- Coordinates for the dorsal hippocampus is about 3.3 mm posterior and about 1.5 mm bilateral to the bregma and about 3.4 mm below the surface of the skull.
- Teflon-coated stainless steel recording electrodes with less than about 0.25-mm bare tips are positioned into dorsal hippocampi bilaterally in the dorsal hippocampi to evaluate the presence or absence of seizure events (rhythmic ictal EEG).
- Stainless steel screws are positioned in the occipital bone to provide reference and ground contacts. All electrodes are attached to wires with pin adapters and then affixed to the skull with dental acrylic. Implantation of miniature EEG radiotransmitter, connection to electrodes and post-surgical analgesia are accomplished as described in section B.
- Rats are monitored by trained personnel and maintained on heating pads having a temperature of about 37 ° C. to aid in the regulation of body temperature.
- About 0.25 to about 0.5 mg/100 g of Butorphanol tartrate (TorbugesicTM, A. J. Buck. Owings Mills, Md.) is administered s.c. at the onset of surgery and thereafter for the treatment of pain as evidenced by the presence of signs of discomfort such as piloerection, hunched posture, inactivity and/or anorexia.
- Rats are observed until they are eating, drinking and resting in a natural position after anesthesia. Rats are individually housed in cages over receivers (RPC 1) and allowed free access to food and water and are maintained on a 12 hour/12 hour light/dark cycle.
- RPC 1 receivers
- the stylet is removed from the guide cannula and replaced with an injection cannula comprising a 24-gauge guide wire, the tip of which is about 0.5-mm length of fused silica (0.075 mm i.d., 0.15 mm o.d.).
- Freely moving animals are injected with an aqueous solution of about 1.5 ⁇ l of about 100 mM ferric chloride (FeCI 3 ) having a pH of about 2.2 at a rate of about 1 ⁇ l per minute using a microinfusion pump.
- Control animals are injected with about 1.5 ⁇ l of about 0.9% NaCl, with pH adjusted to about 2.2.
- EEG determinations are initiated by placing the entire microisolator on top of the Data Sciences International (DSI) Physiotel Receiver Model RPC-1 (St. Paul, Minn.) connected to a Data Exchange Matrix (DSI, St. Paul, Minn.) and a Pentium III 733 Mhz computer using a DSI A.R.T. II System (DSI, St. Paul, Minn.) for Windows NT.
- DSI Data Sciences International
- DSI Data Exchange Matrix
- Pentium III 733 Mhz computer a DSI A.R.T. II System
- EEG is acquired and stored for analysis.
- the transmitter is activated by swiping a magnet over the subcutaneous implantation site, and EEG recording is initiated by placing the rat over the top of an RPC-1 receiver (DSI, St. Paul, Minn.).
- EEG is recorded only for 24 hours. Examples of epileptiform spike and spike/wave patterns are illustrated in FIGS. 3 a and 3 b.
- Specific parameters for data/statistical analysis include the number of seizure events per unit time, seizure duration or duration of rhythmic paroxysmal activity and overall slowing of electrical activity in and power spectral analysis of EEG.
- power spectral analysis identification of a decrease in mean frequency values of the amplitude spectrum of equal to or greater than about 0.5 Hz in two or more of the following frequency bands is indicative of meaningful lesions in tested regions: ⁇ (0.5-5 Hz), ⁇ (5-10 Hz), ⁇ (10-16 Hz), ⁇ (16-48) and total (0-48).
- EEG data is recorded as above on a round-the-clock basis for about 30 days after intra-amygdalar ferric chloride injection. Twenty-four hour videotaping of animals is used to verify behaviors associated with seizures identified by EEG. Behaviors are scored from review of the video images by using the criteria of set forth by Racine, R. (1972) Electroencephalogr. Clin. Neurophysiol. 32:281-294, which is herein incorporated by reference, by an observer blind to the nature of the injectate received by the animals. After about 30 days, rats are tested for memory function in the Morris water maze as described below. After behavioral testing, rats are euthanized, perfused and brains removed, sectioned and stained to ascertain amygdalar placement and identify siderosis.
- treatment with ALA is given s.c., as per Wolz & Kriglstein (1996) Neuropharmacology 35:369-375, which is herein incorporated by reference.
- about 100 mg/kg of ALA and about 50 mg/kg DHLA is administered s.c. about 30 minutes after ferric injection.
- follow-up doses of about 100 mg/kg of ALA and about 50 mg/kg of DHLA are given s.c. at about 3, about 24, about 48 and about 72 hours after ferric chloride.
- About 300 mg/kg of SPBN or 150 mg/kg of PBN is administered s.c. 30 minutes after FP with repeated injections every four hours lasting for about 72 hours.
- alpha-tocopherol In studies examining the effects of vitamin E, about 25 mg/kg of alpha-tocopherol is injected i.p. about 0.5, about 3, about 24, about 48 and about 72 hours after FP. About 50 ⁇ g of selenium is administered i.p. whenever alpha-tocopherol is administered. In all experiments vehicle-treated groups and sham-operated groups are studied which identifies any effects of the compounds tested on EEG or memory. The dosages may be adjusted as necessary.
- ALA is administered s.c. daily for three days prior to FP, followed by about 50 mg/kg s.c. one hour prior to FP.
- ALA is administered only, then about 100 mg/kg of ALA are administered s.c. about 72 hours, about 48 hours, about 24 hours, about 2 hours or a combination thereof prior to FP.
- coenzyme Q 10 is administered, then about 200 mg/kg of coenzyme Q 10 is administered p.o. ⁇ 10 days.
- About 300 mg/kg of SPBN or about 100 mg/kg of PBN is administered s.c. q.i.d. during about 72 hours of pretreatment.
- alpha-tocopherol is administered, about 25 mg/kg is injected i.p. about two hours prior to FP.
- About 50 micrograms i.p. of selenium may be administered when alpha-tocopherol is administered.
- the Morris water maze is used to evaluate the extent to which fluid percussion injury or amygdalar ferric chloride injection impairs a rat's ability to learn the location of a submerged platform in a pool of water.
- the training on the visual recognition memory task is suspended and each rat is trained to swim to the safety of a non-visible submerged platform in a circular pool of water (26 ° C.).
- a rat will be placed randomly at one of four locations (north, south, east, or west) in a circular pool of water and allowed to swim for about 60 seconds.
- the rat locates the submerged platform, it is allowed to remain on the platform for about 10 seconds. But, if the rat fails to locate the platform, at the end of about 60 seconds, it is removed from the pool. 12 learning trials are scheduled/day with about four minute breaks between each learning trial. Similarly, water maze training is accomplished two days prior to surgery for placement of amygdalar ferric chloride cannulae.
- the first water-maze retention test does not occur until the 8 th post-injury day.
- daily tests of visual recognition memory are scheduled for the first seven days after fluid percussion injury.
- visual discrimination assessments are discontinued and five retention trials are scheduled.
- Retention trials are identical in every respect to pre-injury learning trials, including the location of the platform.
- the platform is removed and a probe trial is used to determine whether a rat's preference was controlled by location of the platform or by visibility.
- days 11-14 the location of the platform is changed on successive test days.
- the rat's performance during all learning and retention tests is tracked and quantified by the TSE VideoMot2 (www.TSE-Systems.de) video tracking system. For each rat, the number of entries into the four quadrants (zones) of the pool, time spent in each zone, distance traveled, swim speed, as well as latency to find the platform from the initiation of a trial is collected for each rat.
- TSE VideoMot2 www.TSE-Systems.de
- rats are housed in individual test cages that contain three levers, a dot-pattern module above each lever, and a food trough below the center lever. Initially, a dot pattern is illuminated over one of the side levers and rats are trained to press the lever beneath the illuminated dot pattern. After rats learn to track the location of the dot pattern above the side levers, one of several dot-patterns is illuminated above the center lever. A press on the center lever will turn the sample pattern off and simultaneously illuminate comparison dot patterns above each of the side levers. The dot pattern above one side lever matches the (sample) pattern and the dot pattern above the other lever is different.
- a press on the lever beneath the comparison dot pattern that is different from the sample pattern results in the delivery of food and immediately initiates a 10 second inter-trial interval. At the end of the inter-trial interval, one of the seven dot-patterns is randomly selected for presentation as a new sample.
- a press on the lever beneath the comparison dot pattern that matches the sample dot pattern ends the trial and after a 10 second inter-trial interval, a correction trial is initiated.
- the previous sample is represented as a flashing dot pattern and a press on the center lever results in the representation of the comparison stimuli that appeared on the previous trial.
- the comparison pattern that matches the flashing sample does not flash and the probability is 0.50 that the previous sample will reappear above the same lever.
- a delay of variable duration will be imposed between presentation of the sample pattern and the presentation of the comparison patterns. Prior to FP, different delays between offset of the sample and presentation of the comparison patterns will be used to determine the extent to which the passage of time or activity within the delay interfere with recall of the sample.
- the rats are anesthetized with about 70 mg/kg of ketamine and about 6 mg/kg of xylazine i.m.
- rats are sequentially perfused transcardially with physiological saline which results in euthanasia by exsanguination and about a 10% formalin solution for fixation. Brains are removed and, after additional immersion fixation, paraffin-embedded Nissl-stained tissue sections are prepared.
- Sections from FP-injured and sham rats are examined by specifically focusing on anticipated injury-induced changes in neuronal cell numbers within the hilar region of the dentate gyrus of the hippocampus. Normal neurons are identified by he presence of nuclei with clear nucleoplasm, surrounded by cytoplasm containing Nissl substance. Hilar neuronal cell numbers are counted in six 30 micron non-adjacent sections per Lowenstein et al., (1992) J. Neuroscience 12(12):4846-4853, which is herein incorporated by reference, and compared among treatment groups in subsequent statistical analysis. In addition, other neuroanatomical hallmarks of fluid percussion injury, e.g.
- cortical contusion, hippocampal CA1 and CA3 neurons may be examined, and if suitably consistent within experimental groups, are analyzed by nonparametric, e.g. blinded rater score or parametric, e.g. cell number analysis.
- nonparametric e.g. blinded rater score
- parametric e.g. cell number analysis.
- degenerative changes in the lateral geniculate nucleus are determined as reported by Bauman et al. (2000) Journal of Neurotrauma accepted pending revision, which is herein incorporated by reference.
- the neuroprotective effect of the lipoic acids may be significantly enhanced by the co-administration of SPBN and PBN.
Abstract
Methods of preventing, treating, or both preventing and treating CNS injury, disease, neurotoxicity or memory deficit in a subject by the administration of at least one lipoic acid compound to the subject are disclosed. Examples of CNS injuries or disease include traumatic brain injury (TBI), posttraumatic epilepsy (PTE), stroke, cerebral ischemia, neurodegenerative diseases of the brain such as Parkinson's disease, Dementia Pugilistica, Huntington's disease and Alzheimer's disease, brain injuries secondary to seizures which are induced by radiation, exposure to ionizing or iron plasma, nerve agents, cyanide, toxic concentrations of oxygen, neurotoxicity due to CNS malaria or treatment with anti-malaria agents, and other CNS traumas. Examples of lipoic acid compounds include alpha-lipoic acid (ALA), dihydrolipoic acid (DHLA), 2-(N,N-dimethylamine) ethylamido lipoate-HCL (LA-plus), the oxidized or reduced R- or S-isomers thereof, the metabolites of alpha-lipoic acid such as 6,8-bisnorlipoic acid and tetranorlipoic acid and analogs thereof. Also disclosed are pharmaceutical compositions and kits comprising at least one lipoic acid compound.
Description
- This application claims the benefit of U.S. Provisional Patent Application No. 60/198,958, filed Apr. 21, 2000, naming James L. Meyerhoff, Debra L. Yourick and Michael L. Koenig as inventors, which is herein incorporated by reference.
- [0002] This invention was made by employees of the United States Army. The government has rights in the invention.
- 1. Field of the Invention.
- The invention relates to a method of treating, preventing or inhibiting central nervous system (CNS) injuries and diseases. In particular, the invention relates to a method of treating, preventing or inhibiting a CNS injury or disease in a subject by the administration of at least one lipoic acid compound to the subject.
- 2. Description of the Related Art.
- Traumatic brain injury (TBI) can initiate a cascade of events which may lead to dramatic elevation of intracranial pressure (ICP), cerebral edema, ischemia, intracranial hemorrhage and dysfunction of cerebrovascular regulatory mechanisms essential for survival. Deficits in memory, attention, and perception, emotional disorders, social behavioral problems, seizures (including non-convulsive seizures), paralysis, aphasia, post-traumatic epilepsy (PTE), and oxidative stress-induced neurotoxicity may result from TBI.
- In several studies of severely head-injured patients, over 80% had ischemic damage in the hippocampus. See McIntosh, T. K., et al., (1996) Laboratory Investigation 74(2):315-342. The hippocampal damage may explain the prevalence of memory defects in survivors of TBI. Generally, the two main stages in the development of TBI are (1) primary, including contusion, laceration, intracranial hemorrhage and diffuse axonal injury; and (2) secondary, including delayed effects such as seizures, ischemia, edema, and biochemical reactions, which lead to necrosis and apoptosis.
- Penetrating brain injuries, associated with retained intracranial ferric metal fragments and inevitably associated with hemorrhage, are highly likely to produce posttraumatic epilepsy (PTE). See Salazar, A. M., et al., (1985) Neurology 35:1406-1414. Development of seizures following penetrating craniocerebral trauma has been associated with the presence of hematoma, total brain volume loss, presence of retained metal fragments, hemiparesis, aphasia, visual field loss, organic mental disorder, headache and a history of seizures during the first year post injury.
- Initial events in TBI such as hemorrhage and ischemia can elicit activation of leukocytes and excessive release of the excitatory neurotransmitter glutamic acid with resulting excess influx of calcium. These events can trigger a number of interactive intermediate reactions which can lead ultimately to neurotoxicity. These include decompartmentalization of iron, and the activation of several enzymes including phospholipases, xanthine oxidase, intraneuronal nitric oxide synthase and poly[ADP-ribose]polymerase (PARP). Formation of neurotoxic reactive oxygen species (ROS) appears to be a result common to many of these “initiator” pathways and is a major “perpetrator” in mediating necrotic neuronal death. For example, it is well-known that glutamate, acting via both NMDA and non-NMDA receptors, leads to increased intraneuronal calcium, which in turn may activate (a) phospholipase A2, triggering arachidonic acid production, or (b) xanthine oxidase. Both pathways lead to the production of free radicals, such as superoxide. Additional pathways leading to free radical formation include liberation of “catalytic” iron from extravasated hemoglobin and decompartmentalization of iron or copper from damaged mitochondria. Thus, although the immediate mechanisms of pathologic responses to nervous system may vary, many forms of neurotoxicity are believed to share a common final pathway via formation of ROS, reactive nitrogen species, or both. ROS are most aggressively damaging in the central nervous system (CNS) as ROS attack double bonds in the unsaturated fatty acids, which are abundant in CNS membranes, to form carbon-centered radicals (R) or (R-HC-R) wherein “R” generally refers to any carbon chain which length may vary. These radicals initiate a chain reaction of lipid peroxidation, which continues until arrested by the formation of a relatively non-reactive species such as oxidized vitamin E or vitamin C. Scavengers, such as vitamin E, also known as alpha-tocopherol, donate a hydrogen atom to a radical, thereby becoming a secondary radical. Since the tocopherol radical is rather stable, it breaks the chain reaction, hence these scavengers are known as “chain-breaking antioxidants”.
- The several neurotoxic pathways can produce a variety of small, diffusible ROS, including superoxide, nitric oxide, peroxyl, perhydroxyl, peroxynitrite, hypochlorous and singlet oxygen. The antioxidant enzyme superoxide dismutase converts the superoxide radical to hydrogen peroxide, a non-radical oxidizing agent that can engage in a number of iron-catalyzed reactions producing the very toxic hydroxyl ion. For example, the ferrous ion can trigger the Fenton reaction with hydrogen peroxide to form hydroxyl ions plus a ferric ion. Iron ions can also catalyze the Haber-Weiss reaction, in which superoxide and hydrogen peroxide react to form hydroxyl ions and molecular oxygen. Superoxide can also react with nitric oxide to produce the intermediate peroxynitrite, which subsequently yields the hydroxyl radical.
- Although a particular neurotoxic reaction might predominate initially, other pathways may rapidly be recruited, thereby exacerbating damage. For example, hemoglobin, a potential source of catalytic iron, potentiates excitatory amino acid-induced neurotoxic injury in cortical cell culture. Ischemia is a secondary effect of TBI and causes a metabolic imbalance wherein mitochondria increase production of ROS while decreasing production of energy required for neuronal homeostasis, engendering oxidative stress. Injury-induced activation of PARP can deplete NAD+, and consequently also deplete ATP. Depletion of energy sources such as ATP transforms glutamic acid from neurotransmitter to neurotoxin. Moreover, ROS exacerbate the excitotoxic pathways by increasing the release of glutamate and inhibiting its reuptake inactivation.
- There are important endogenous antioxidant defenses in the central nervous system which are essential in providing cellular resilience in response to injury. These protective mechanisms include glutathione (GSH), alpha-lipoic acid (ALA), dihydrolipoic acid (DHLA), coenzyme Q, vitamin E, vitamin C, pyruvate, melatonin, and niacinamide. Some of these are synthesized endogenously and some are dietary requirements. The sulfhydryl group of GSH is particularly important in protecting cell membranes against peroxidative stress. GSH peroxidase, using GSH as a co-substrate and selenium as a metallic cofactor, reduces intracellular formation of hydrogen peroxide and free radicals.
- Unfortunately, these endogenous antioxidant defenses in the central nervous system are not sufficient to prevent or inhibit TBI, PTE and other related CNS traumas. Consequently, various compounds and treatments have been developed.
- Additionally, recent clinical trials of Tirilazad™ (Upjohn) and Peg-SOD (superoxide dimutase linked to polyethylene glycol) have been disappointing, their design has been controversial, and leaves the question of the value of antioxidants unresolved. See Marshall, S. B., et al., (1998) J. Neurosurg. 89(4):519-525. Tirilazad™ is an antioxidant aminosteroid which proved to be clinically unsuccessful against stroke because it did not readily cross the blood brain barrier and it failed to protect the hippocampus. Furthermore, a number of large clinical trials have failed to demonstrate a benefit of administering phenytoin, phenobarbital, carbamazepine or valproate as a way to prevent the onset of PTE.
- Clearly, a need exists for effectively treating and preventing TBI, PTE and other CNS traumas.
- In some embodiments, the present invention relates to a method of treating a subject suffering from a CNS injury or disease comprising administering to the subject a composition comprising a therapeutically effective amount of at least one lipoic acid compound.
- In some embodiments, the present invention relates to a method of preventing or inhibiting a CNS injury or disease in a subject comprising administering to the subject a composition comprising a therapeutically effective amount of at least one lipoic acid compound.
- In some embodiments, the invention relates to a method of preventing, inhibiting or treating neurotoxicity or memory deficit in a subject comprising administering to the subject a composition comprising a therapeutically effective amount of at least one lipoic acid compound.
- Where the memory deficit may be induced by electroconvulsive shock therapy for treating diseases and disorders such as depression and schizophrenia, the composition may be administered before the electroconvulsive shock therapy to mitigate memory loss.
- In some embodiments, the CNS injury or disease may be traumatic brain injury (TBI), posttraumatic epilepsy (PTE), stroke, cerebral ischemia, or a neurodegenerative disease. In some embodiments, CNS injury may be induced by fluid percussion, a blunt object impacting the head of the subject, an object which penetrates the head of the subject, or exposure to radiation, ionizing or iron plasma, a nerve agent, cyanide, toxic concentrations of oxygen, CNS malaria, or an anti-malaria agent.
- In the embodiments of the invention, the lipoic acid compound may be alpha-lipoic acid (ALA), dihydrolipoic acid (DHLA or DHL), 2-(N,N-dimethylamine) ethylamido lipoate-HCL (LA-plus), the oxidized or reduced R- or S-isomers, a metabolite of α-lipoic acid, or an analog thereof. In preferred embodiments, the lipoic acid compound is ALA, DHLA, or LA-plus.
- In some embodiments of the invention, the composition may further comprise at least one ROS scavenger. Suitable ROS scavengers include coenzyme Q, vitamin E, vitamin C, pyruvate, melatonin, niacinamide, N-acetylcysteine, GSH, and nitrones.
- In the embodiments of the present invention, the therapeutically effective amount of the lipoic acid compound administered to the subject is about 0.001 mg to about 20 mg per kg of the subject, preferably about 1 mg to about 10 mg per kg of the subject, more preferably about 3 mg to about 10 mg per kg of the subject.
- In some preferred embodiments, the total daily amount of the lipoic acid compound administered to the subject is about 50 mg to about 1200 mg, preferably about 100 mg to about 1000 mg, more preferably about 200 mg to about 800 mg, even more preferably about 300 mg to about 600 mg.
- In some embodiments, the invention relates to administering the lipoic acid compound to a subject a period of time before the subject is exposed or likely to be exposed to a risk of CNS injury or damage or before the subject is exposed to conditions likely to cause neurotoxicity or memory deficit or both. The conditions likely to cause CNS injury or damage, neurotoxicity or memory deficit include electroconvulsive shock therapy, traumatic brain injury (TBI), posttraumatic epilepsy (PTE), stroke, cerebral ischemia, neurodegenerative diseases, fluid percussion, a blunt object impacting the head of the subject, an object penetrating the head of the subject, radiation, ionizing or iron plasma, nerve agents, cyanide, toxic concentrations of oxygen, CNS malaria, and anti-malaria agents. Other conditions likely to cause CNS injury or damage, neurotoxicity or memory deficit include certain medical procedures or conditions associated with risk for CNS ischemia, hypoxia or embolism such as brain tumor, brain surgery, open heart surgery, carotid endarterectomy, repair of aortic aneurysm, atrial fibrillation, cardiac arrest, cardiac or other catheterization, phlebitis, thrombosis, prolonged bed rest, prolonged stasis (such as during space travel or long trips via airplane, rail, car or other transportation), CNS injury secondary to air/gas embolism or decompression sickness.
- The period of time may be about 72 hours to about the time of expected exposure, preferably about 48 hours to about the time of expected exposure, more preferably about 12 hours to about the time of expected exposure, even more preferably about 4 hours to about the time of expected exposure, and most preferably about 2 hours to about the time of expected exposure.
- The administration of the lipoic acid compound may be continuous from the initial time of treatment to the end of treatment. For example, a transdermal patch or a slow-release formulation may be used to continually administer the lipoic acid compound to the subject for a given period of time. Alternatively, the lipoic acid compound may be administered to the subject periodically. For example, the lipoic acid compound may be first administered at about 24 hours before the time of expected exposure and then administered at about every 2 hours thereafter. In some embodiments, at least one ROS scavenger such as coenzyme Q, vitamin E, vitamin C, pyruvate, melatonin, niacinamide, N-acetylcysteine, GSH, or a nitrone, is administered prophylactically in combination with the prophylactic administration of the lipoic acid compound.
- In the embodiments of the invention, the composition may further comprise a pharmaceutically acceptable excipient. The composition may be administered intravenously, intradermally, subcutaneously, orally, transdermally, transmucosally or rectally. Preferably, the composition is orally administered.
- In some embodiments, the invention relates to a pharmaceutical composition for treating or preventing CNS injury, disease or neurotoxicity in a subject comprising a therapeutically effective amount of at least one lipoic acid compound and a pharmaceutically acceptable excipient. The lipoic acid compound may be ALA, DHLA, LA-plus, the oxidized or reduced R- or S-isomers, a metabolite of ALA, or an analog thereof. The pharmaceutical composition may further comprise at least one ROS scavenger. Examples of suitable ROS scavengers include coenzyme Q, vitamin E, vitamin C, pyruvate, melatonin, niacinamide, N-acetylcysteine, GSH, and nitrones.
- In some embodiments, the invention relates to a kit comprising a composition comprising a therapeutically effective amount of at least one lipoic acid compound. The lipoic acid compound may be ALA, DHLA, LA-plus, the oxidized or reduced R- or S-isomers, a metabolite of ALA, or an analog thereof. In a preferred embodiment, the lipoic acid compound is ALA, DHLA, or LA-plus. The kit or the composition may further comprise at least one ROS scavenger. Suitable ROS scavengers include coenzyme Q, vitamin E, vitamin C, pyruvate, melatonin, niacinamide, N-acetylcysteine, GSH, and nitrones. The kit may further comprise a device for administering the composition to a subject such as an injection needle, an inhaler, a transdermal patch. The kit may also comprise instructions for use.
- This invention is further understood by reference to the drawings wherein:
- FIG. 1 illustrates that DHLA is protective in a concentration-related manner against hemoglobin-induced toxicity in cultured neurons in vitro.
- FIG. 2 illustrates that DHLA is protective against experimental spinal cord injury in rats in vivo.
- FIG. 3a is an example of an iron-induced paroxysmal spiking seizure on electroencephalogram (EEG) in rat.
- FIG. 3b is an example of an iron-induced spike-and-wave seizure on electroencephalogram (EEG) in rat.
- FIG. 4 illustrates that pretreatment with ALA and co-treatment with DHLA reduces iron chloride-induced seizure activity by about 55%.
- FIG. 5 illustrates the neuroprotective effects of DHL and SPBN.
- FIG. 6 illustrates the neuroprotective effects of DHL and PBN.
- The present invention relates to a method of preventing, treating, or both preventing and treating a CNS injury or disease by the administration of at least one lipoic acid compound.
- Examples of CNS injuries or disease include TBI, stroke, concussion (including post-concussion syndrome), cerebral ischemia, neurodegenerative diseases of the brain such as Parkinson's disease, Dementia Pugilistica, Huntington's disease and Alzheimer's disease, brain injuries secondary to seizures which are induced by radiation, exposure to ionizing or iron plasma, nerve agents, cyanide, toxic concentrations of oxygen, neurotoxicity due to CNS malaria or treatment with anti-malaria agents, and other CNS traumas. Examples of lipoic acid compounds include alpha-lipoic acid (ALA), dihydrolipoic acid (DHLA or DHL), 2-(N,N-dimethylamine) ethylamido lipoate-HCL (LA-plus), the oxidized or reduced R- or S-isomers, the metabolites of ALA such as 6,8-bisnorlipoic acid and tetranorlipoic acid and analogs thereof. Analogs of lipoic acid compounds include lipoamides.
- ALA is a physiological constituent of mitochondrial membranes and is an essential cofactor in the oxidative decarboxylation of alpha-keto acids such as pyruvate and alpha-ketoglutarate. ALA is present in food and in mammalian tissues. ALA is clinically safe, well-tolerated and is currently used to treat peripheral neuropathy in patients with diabetes. ALA is stable in tablet form, can be given orally, has good bioavailability in humans, is well-tolerated and is endogenously converted to DHLA.
- Both ALA and DHLA are effective scavengers of numerous ROS and have been shown to be neuroprotective in several rodent models of cerebral ischemia. They are rapidly distributed to the central nervous system, improve memory, are active in both lipid and aqueous phases, and increase intracellular levels of GSH and ATP.
- ALA and DHLA may be used in methods for treating or prevention TBI, PTE and other CNS traumas. In particular, they protect neurons, among other things, by (1) acting as direct chain-breaking antioxidants; (2) recycling the antioxidant vitamins C and E; (3) scavenging at least 8 types of free radicals; (4) chelating decompartmentalized iron ions; (5) chelating copper ions; (6) increasing intracellular energy stores which include ATP; (7) regenerating and increasing intracellular levels of the endogenous antioxidant, glutathione; (8) increasing the ratio of reduced to oxidized coenzyme Q; and (9) providing methionine sulfoxide reductase with reducing equivalents. DHLA also enhances the repair of oxidatively damaged proteins.
- As illustrated in FIG. 1, DHLA was recently demonstrated to be protective in a concentration-related manner (about 0.3 to about 10 micromolar) against hemoglobin-induced toxicity in cultured neurons in vitro. See Koenig et al., (1999) Neurosci. Abs., 25, which is herein incorporated by reference. Here, primary cultures of neurons derived from the forebrains of E-15 rat fetuses were pre-incubated with DHLA at several different concentrations for about 4 hours. The neurons were then exposed to about 10 micromoles of hemoglobin and resulted in about 50% viability after about a 24 hour exposure. Neuronal viability was assessed by using the colorimetric MTT assay of succinate dehydrogenase activity. MTT is a colorimetric dye, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, and is available from Sigma. Neuroprotection increased with increasing concentrations of DHLA. There was no evidence of neuroprotection where DHLA was coapplied with hemoglobin.
- As illustrated in FIG. 2, DHLA was also demonstrated to be protective against experimental spinal cord injury in rats in vivo. Here, about 5 micromoles of DHLA was administered intrathecally as a 2 hour pretreatment. Flaccid paralysis was acutely evident about 10 minutes after injection with dynorphin A and where there was no pretreatment with DHLA or co-treatment with DHLA. Pretreatment with DHLA and treatment after injury with DHLA was observed to improve motor scores. See Long et al., (1999) Neurosci. Abs. 25, which is herein incorporated reference.
- A modified Willmore model of ferric chloride-induced epilepsy may be used to automatically record and quantify seizure activity on a 24 hour basis as shown in FIGS. 3a and 3 b. Here, ferric chloride was injected into the cerebral cortex of a rat which elicits intense seizures. FIG. 3a shows an example of an electroencephalograph (EEG) paroxysmal spiking seizure pattern. FIG. 3b shows an example of an EEG “spike and wave” seizure pattern. By using this modified neurotoxic model, as illustrated in FIG. 4, pretreatment with (α-LA and co-treatment with DHLA reduced iron chloride-induced seizure activity by about 55%. In this experiment, male Sprague Dawley rats were injected with 100 mg/kg of ALA i.p. once daily for 48 hours then anesthetized and 50 mg/kg of DHLA was injected i.p. after which 600 micromolar of ferric chloride was injected unilaterally intracortically. EEG was recorded for 24 hours and sampled for 10 seconds for each 60 seconds over a period of 24 hours. To achieve uniformly quantitative information, the number of seconds of seizure activity was measured in every sampled 10 seconds. As shown in FIG. 4, rats pretreated with alpha-LA and DHLA had about 55% less seizure activity than rats that were not pretreated.
- LA-plus is a positively charged water soluble lipoic acid amide analog which shows a higher rate of intracellular reduction and retention than is seen with ALA, as well as better in vitro protection against glutamate-induced loss of GSH, formation of peroxide and neurotoxicity in cultured mouse hippocampal HT4 cells. See Tirosh et al., (1999) Free Rad. Biol & Med. 26(11/12):1418-1426, which is herein incorporated by reference. In addition to the administration of a lipoic acid compound, at least one ROS scavenger may also be administered. Examples of ROS scavengers include coenzyme Q, vitamin E, vitamin C, pyruvate, melatonin, niacinamide, N-acetylcysteine, GSH and nitrones.
- The neuroprotective efficacy of the lipoates may be enhanced by supplementary compounds. For example, the neuroprotective efficacy of the lipoates might be enhanced by (1) combination with other free radical scavenger with slightly differing mechanisms of action (e.g. coenzyme Q; or nitrones); or (2) with other classes of neuroprotectants with fundamentally different mechanisms, such as the neurotrophic factors brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophins (e.g. NT-3) and/or the neuroprotective endogenous TRH analog, pyroGlu-Glu-Pro (known by its abbreviation, EEP).
- Coenzyme Q10 (CoQ10), also known as ubiquinone, is an endogenous molecule that transports electrons in mitochondria, as part of the process of ATP generation. CoQ10 levels in spinal cord have been reported to be decreased following injury and the changes were found to be reflective of the degree of trauma.
Ubiquinone 10 has been found to be a lipid-soluble antioxidant which can prevent lipid peroxidation in brain synaptosomes and mitochondria, recycle vitamin E and scavenge ROS. Pretreatment with coenzyme Q reduced 33malonate-induced neurotoxicity in vivo. See Beal et al., (1994) Eur. J. Pharmacology-Molec. Pharm. Section 266:291-300, which is herein incorporated by reference. Although some studies reported that it was therapeutically efficacious in certain clinical situations, others have found it ineffective. See Nishikawa et al., (1989) Neurol. 39:399-403; Matthews, et al., (1993) Neurol. 43:884-890, which are herein incorporated by reference. However, it is clearly an antioxidant neuroprotectant which may be synergistic with alpha-LA much as it synergizes with niacinamide. See Gotz et aL, (1994) Eur. J. Pharmacology - Molec. Pharm. Section 266:291-300; Beal, et al., (1994) Ann. Neurol. 36:882-888, which are herein incorporated by reference. Accordingly, coenzyme Q may be co-administered with the lipoic acids of the invention. - Nitrone-based free radical traps (nitrones) such as alpha-Phenyl-N-tert-butylnitrone (PBN), N-tert-Butyl-α-(2-sulfophenyl)nitrone (SPBN), Azulenyl nitrones, and NXY-059, offer a ROS scavenging mechanism which differs from vitamin E, the lipoic acids and other endogenous compounds. The nitrones react covalently with ROS to form stable nitroxides. They have also been shown to be neuroprotective against glutamate-induced toxicity in cultured neurons as well as in several rodent models of cerebral ischemia, including transient global ischemia, transient and permanent occlusion of the middle cerebral artery. Therefore, nitrones may be co-administered with the lipoic acids of the invention.
- SPBN is an effective neuroprotectant without significant toxicity. The free radical scavenger SPBN is synergistic with brain-derived neurotrophic factor (BDNF) in survival of axotomized retinal ganglion cells. See Klocker et al., (1998) J. Neurosci. 18(3):1038-1046, which are herein incorporated by reference. Thus, BDNF may be co-administered with the lipoic acids of the invention. PBN is a nitrone which has been shown to be neuroprotective in animal models of ischemia, even when administered post injury. PBN is also effective as a pre-treatment against DFP-induced convulsions.
- As described in Example 7 and shown in FIGS.5 and 6, since nitrones have more than one mode of action, as do the lipoic acids, and since the scavenging mechanisms of nitrones and lipoic acids differ, nitrones may be co-administered with lipoic acids to provide a synergistic neuroprotective effect.
- Since one group of compounds such as lipoic acids might be more suitable for pretreatment, and another group such as nitrones might be more suitable for post-injury treatment, the times and amounts that the lipoic acid compounds and the supplementary compounds are administered may be varied. For example, an individual known to be at risk for certain injuries may be administered a lipoate. After an injury occurs, the individual would be administered a supplementary active compound such as a nitrone, trophin, or other free radical scavenger. The lipoate administered before the injury would confer a protection at the time of injury and afterwards. The post-injury administration of the supplementary active compound would provide a synergistic neuroprotective effect with the lipoate.
- A tripeptide comprising three linked amino acids, pyroglutamate-glutamate-proline-amide, which is referred to as EEP, is structurally similar to thyrotropin releasing hormone (TRH) which comprises pyroglutamate-histidine-proline. Both EEP and TRH are found in the brain. Like TRH, EEP is neuroprotective against Glutamate-induced neurotroxicity. But unlike TRH, EEP is not hydrolyzed in plasma by the TRH-hydrolyzing enzyme thyroliberinase. Thus, EEP has better clinical neuroprotective potential than TRH. However, either EEP or TRH or both may be administered in combination with the lipoic acids of the invention.
- Vitamin E, alpha-Tocopherol, is a normal dietary component and prevents peroxidative injury of sulfhydryl groups of glycolipids and glycoproteins by augmenting the antioxidant effects of enzyme systems such as glutathione peroxidase. It stimulates the synthesis of ATP, decreases lipid peroxidation, attenuates neurotoxic effects of iron in vitro, and prevents iron-induced seizures in vivo. Although vitamin E exhibits a slow rate of absorption through the blood brain barrier and is not suitable in methods to rapidly treat a brain injury, vitamin E may be suitable for prophylactic treatments and treatments over long periods of time.
- As ischemia induces a significant decrease of the activity of E1 component of the pyruvate dehydrogenase complex and DHLA protects the E1 component from chemical inactivation, the lipoic acid compounds of the present invention may be coupled via an amide linkage to one of the three enzymes of the pyruvate dehydrogenase complex.
- In the method of the present invention, a therapeutically effective amount of at least one lipoic acid compound or an analog thereof may be given prophylactically to a subject having a high risk for obtaining a CNS injury or disease. A subject pretreated with a lipoic acid compound or analog thereof would have an increased antioxidant reserve and would therefore have an increased resistance to CNS injuries and diseases. Administration of the lipoic acid compound may be continued after obtaining the CNS injury or disease.
- Lipoic acid compounds may be administered to a subject as a method of preventing or treating CNS damage induced by exposure to nerve agents such as Soman, sarin, VX and the like. Soman elicits a sustained increase in extracellular glutamate levels in the amygdala, induces the de-compartmentalization of iron in brain tissue and catalyzes the formation of ROS.
- Lipoic acid compounds may be administered to a subject as a method of preventing or treating radiation-induced CNS damage as inhibition of free radical formation provides neuroprotection to cultured cortical neurons exposed to ionizing radiation and injections of lipoic acid protects hematopoietic tissues in gamma-irradiated mice. Lipoic acid should also protect against injury to CNS, cardiac and hematopoeitic tissues secondary to cancer chemotherapy.
- Additionally, lipoic acid compounds may be administered to a subject suffering from CNS malaria or a subject being treated with Arteether and related antimalarial compounds as a method to prevent or treat CNS damage.
- Further, the lipoic acid compounds may be administered to a subject exposed to high oxygen under pressure (OHP) as the pathophysiological mechanism in toxicity induced by OHP may involve free radical generation. OHP causes seizures and convulsions.
- The lipoic acid compounds may be administered prophylactically to a subject at risk for CNS injury or disease. Subjects at risk for CNS injury or disease include participants in contact sports such as football and boxing, military personnel, astronauts and others at risk for exposure to blast overpressure, blunt head trauma, and penetrating brain injury. The lipoic acid compounds may be administered intravenously, intradermally, subcutaneously, orally, transdermally, transmucosally or rectally.
- A therapeutically effective amount of the lipoic acid compound of the invention may be administered to a subject a period of time before the subject is exposed to a risk of CNS injury or damage or before the subject is exposed or likely to be exposed to conditions likely to cause neurotoxicity or memory deficit or both. The conditions likely to cause CNS injury or damage, neurotoxicity or memory deficit include electroconvulsive shock therapy, traumatic brain injury (TBI), posttraumatic epilepsy (PTE), stroke, cerebral ischemia, neurodegenerative diseases, fluid percussion, a blunt object impacting the head of the subject, an object penetrating the head of the subject, radiation, ionizing or iron plasma, nerve agents, cyanide, toxic concentrations of oxygen, CNS malaria, and anti-malaria agents. The period of time may be about 72 hours to about the time of expected exposure, preferably about 48 hours to about the time of expected exposure, more preferably about 12 hours to about the time of expected exposure, even more preferably about 4 hours to about the time of expected exposure, and most preferably about 2 hours to about the time of expected exposure. It is to be understood, however, that the lipoic acid compound may be administered at a period of time which is more than about 72 hours before the time of expected exposure. For example, the period of time may be about 7 days before the expected exposure. The administration of the lipoic acid compound may be continuous from the initial time of treatment to the end of treatment. For example, a transdermal patch or a slow-release formulation may be used to continually administer the lipoic acid compound to the subject for a given period of time. Alternatively, the lipoic acid compound may be administered to the subject periodically. For example, the lipoic acid compound may be first administered at about 24 hours before the time of expected exposure and then administered at about every 2 hours thereafter.
- ROS scavengers such as coenzyme Q, vitamin E, vitamin C, pyruvate, melatonin, niacinamide, N-acetylcysteine, GSH, and nitrones may also be administered prophylactically along with the lipoic acid compound. For example, as described in Beal, M. F., et al., (1994) Ann. Neurol. 36:882-888, which is herein incorporated by reference, therapeutically effective doses of coenzyme Q may be administered in combination with therapeutically effective doses of a lipoic acid compound. Additionally, neurotrophic factors such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophins, and analogs thereof, may be administered prophylactically along with the lipoic acid compound.
- The therapeutically effective amount of the lipoic acid compound administered prophylactically to the subject may be about 0.001 mg to about 20 mg per kg of the subject, preferably about 1 mg to about 10 mg per kg of the subject, more preferably about 3 mg to about 10 mg per kg of the subject. The total daily amount of the lipoic acid compound administered prophylactically to the subject may be about 50 mg to about 1200 mg, preferably about 100 mg to about 1000 mg, more preferably about 200 mg to about 800 mg, even more preferably about 300 mg to about 600 mg.
- The lipoic acid compounds of the invention may be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise at least one lipoic acid or at least one analog thereof and a pharmaceutically acceptable carrier. As used herein the language “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds such as ROS scavengers may also be incorporated into the compositions. Other supplementary active compounds include neurotrophic factors such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophins, and analogs thereof.
- A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral, transdermal, transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application may include a sterile diluent such as water for injection, a saline solution, a fixed oil, a polyethylene glycol, glycerine, propylene glycol or other synthetic solvent, an antibacterial agent such as benzyl alcohol or methyl paraben, an antioxidant such as ascorbic acid or sodium bisulfite, a chelating agent such as ethylenediaminetetraacetic acid, a buffer such as an acetate, citrate or phosphate and an agent for the adjustment of tonicity such as sodium chloride or dextrose. pH may be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. Parenteral preparations may be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier may be a solvent or dispersion medium containing water, ethanol, a polyol such as glycerol, propylene glycol, and liquid polyetheylene glycol, and the like, and suitable mixtures thereof. The proper fluidity may be maintained by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion or by the use of surfactants. Prevention of the action of microorganisms may be achieved by various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, isotonic agents such as sugars, polyalcohols such as manitol, sorbitol, sodium chloride may be used in the composition. Prolonged absorption of the injectable compositions may be brought about by including an agent which delays absorption such as aluminum monostearate and gelatin.
- Sterile injectable solutions may be prepared by incorporating the lipoic acid compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the lipoic acid compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the lipoic acid compound may be incorporated with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, adjuvants, or both may be included as part of the composition. The tablets, pills, capsules, troches and the like may contain a binder such as microcrystalline cellulose, gum tragacanth or gelatin, an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch, a lubricant such as magnesium stearate or Sterotes, a glidant such as colloidal silicon dioxide, a sweetening agent such as sucrose or saccharin, or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- For administration by inhalation, the compounds may be delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
- Systemic administration may also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
- The active compounds may be prepared with carriers which protect the lipoic acid compounds against rapid elimination from the body, such as a controlled release formulation, implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid may be used. Methods of preparing these formulations will be apparent to those skilled in the art. The materials may also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art.
- The pharmaceutical compositions may be formulated in dosage unit forms for ease of administration and uniformity of dosage. A dosage unit form, as used herein, refers to a physically discrete unit suitable for use as a unitary dosage for the subject to be treated. Each unit may contain a predetermined quantity of the lipoic acid compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit form of the invention is dictated by and directly dependent on the unique characteristics of the particular lipoic acid compound and the particular therapeutic effect to be achieved.
- Toxicity and therapeutic efficacy of the particular lipoic acid compound may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Lipoic acid compound which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
- The data obtained from the cell culture assays and animal studies may be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.
- As defined herein, a therapeutically effective amount of the lipoic acid compound of the present invention (i.e., an effective dosage) ranges from about 0.001 mg to about 200 mg per kg of the subject, preferably about 25 mg to about 125 mg per kg of the subject, more preferably about 50 mg to about 100 mg per kg of the subject. Where the subject is human, the therapeutically effective amount ranges from about 0.001 mg to about 20 mg per kg of the human, preferably about 1 mg to about 10 mg per kg of the human, more preferably about 3 mg to about 10 mg per kg of the human.
- The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a lipoic acid compound can include a single treatment or a series of treatments. Administration of the lipoic acid compound may be administered prophylactically before CNS trauma, in individuals at risk. The lipoic acid compound may be administered during and after CNS trauma. It is appreciated that the effective dosage of the lipoic acid compound may increase or decrease over the course of a particular treatment.
- The following examples are intended to illustrate but not to limit the invention.
- Primary cultures may be established following the procedures outlined by Koenig, M. L., et al., (1996) Brain Res. 730:143-149, which is herein incorporated by reference. The forebrains of fetal rat pups (embryonic day 15) are isolated and the cells are dispersed by repeated trituration in neuronal culture medium (NCM). NCM comprises a 1:1 ratio of Ham's F-12 (Biofluids, Rockville, Md.) to Basal Medium Eagle (Sigma, St. Louis, Mo.), supplemented with 0.6 g/L of dextrose, 0.35% glutamine and 1% Pen-Strep (Biofluids, Rockville, Md.). Following centrifugation at 900× g for 5 minutes, the cells are plated onto poly-L-lysine-coated 48 well plates at a density of 106 cells/ml. To suppress glial growth, the cultures are treated with cytosine arabinoside (10−5 M) for 4 days. All cultures are maintained in an incubator comprising 5% CO2 at 37° C. for about 6 days to about 15 days prior to use.
- The cultured rat forebrain neurons are subjected to oxidative stress using hydrogen peroxide following the well-characterized paradigm by Desagher, S., et al., (1997) J. Neuroscience 17(23):9060-9067, which is herein incorporated by reference.
- Oxidative injury is assessed by using an MTT assay (Sigma, St. Louis, Mo.). About 24 h after exposure to either hemoglobin or an oxidative insult, MTT is added to each test well such that the final concentration of the dye is about 0.15 mg/ml. Plates are returned to the incubator for about 1 hr at which time unincorporated MTT is removed and the plates are allowed to air dry. The purple formazan product indicative of viable cells is then dissolved by adding about 250 μl of acidified isopropanol comprising about 95% isopropanol and about 5% 2N HCI. About 200 μl aliquots are collected and the absorbance of these aliquots are measured on an ELISA plate reader at about 540 nm. Control (untreated) wells are included in each experiment, and viability is calculated as the percentage of mean control values for each plate.
- The concentrations of ALA and LA-plus are about 25, about 50 and about 100 micromolar. The concentrations of selenium are about 10 and about 20 micromolar. The concentrations of pyruvate are about 0.3, about 1.0, and about 3.0 mM. The concentrations of SPBN ranges from about 1 to about 50 mM.
- These studies are evaluated by multi-way analysis of variance. When a significant F score is found, an a posteriori or a priori test involving a multiple comparison of means, whichever is appropriate, is used to compare individual treatment groups.
- Male Sprague-Dawley rats weighing about 250 g to about 350 g, pretrained in neurobehavioral tasks described below, are surgically prepared for fluid percussion (FP) injuries using standard surgical procedures known in the art. See Long, J. B., et al., (1996) J. Neurotrauma 13:149-162, which is herein incorporated by reference. Surgical instruments and materials are steam-sterilized using an autoclave and are resterilized between repetitive surgeries using heated glass beads such as Steri 350, which are available from Inotech Biosystems Inc. (Lansing, Mich.).
- Briefly, about 24 hr prior to the experiment, rats are anesthetized with about 70 mg/kg of ketamine and about 6 mg/kg xylazine administered i.m. and the scalp is shaved. The anesthetized rat is then placed in a stereotaxic apparatus and a surgical scrub of the scalp is performed. Using a one cc syringe and a 27 ga needle, the scalp is infiltrated with about 0.2 ml of a 1% lidocaine solution, a midline incision is made, and the scalp and temporal muscles are reflected.
- Using a 4.8 mm diameter trephine, a craniotomy centered over the right parietal cortex is performed, leaving the dura intact. A stainless steel screw is inserted into the skull about 1 mm rostral to bregma. A plastic luer adapter (2.6 mm I.D., about 4.8 mm O.D.) is snugly seated into the craniotomy over the exposed dura, secured to the skull with cyanoacrylate adhesive, and embedded in dental acrylic. The connector is packed with sterile cotton and the surgical site is treated with bacitracin and lidocaine ointments. Rats are observed post-operatively and kept warm with a Vetko (Stoelting, Wood Dale, Ill.) thermal barrier until recovery from anesthesia (i.e. ambulatory), at which time they are returned to their home cages.
- After being retested in the visual discrimination task to ensure a return to presurgery levels of accuracy the rats are anesthetized with halothane and prepared with femoral vein and tail artery catheters in experiments employing secondary hypoxia. Under aseptic conditions, the vessels are exposed by blunt dissection and
PE 50 catheters filled with a sterile heparinized saline, about 10 USP units/ml, are inserted and secured using 3-O nylon sutures. Patency of the i.v. cannulae is maintained with about 0.2 ml flushes with heparinized saline immediately following drug or vehicle injections. The halothane anesthesia is maintained using compressed air and a continuous flow anesthesia system available from Stoelting (Wood Dale, Ill.) in combination with a Fluovac (Stoelting, Wood Dale, Ill.) halothane scavenger, which recaptures anesthetic gases by vacuum and thereby minimizes the escape of halothane to the ambient air. - The spontaneously breathing, anesthetized rats are then positioned in a stereotaxic apparatus, and the luer cranial connector is exposed, filled with sterile saline, and attached to a fluid percussion device, available from Dragonfly (Ridgeley, W. Va.). Briefly, with this device a fluid pressure pulse is generated in a 1 {fraction (1/16)} in. bore stainless steel cylinder with a 3 in. piston stroke that is filled with sterile water and connected to the cranial luer adapters using flexible high pressure tubing (0.089 in. i.d.). The injury is induced by striking the opposing piston with a weighted metal pendulum released from a predetermined height. The resultant rapid injection of a small volume of saline into the closed cranial cavity causes a pulse of increased intracranial pressure that is associated with a brief deformation of brain tissue. The pressure pulse is measured extracranially by a pressure transducer, Model 211B4, available from Kistler Instruments Corp. (Amherst, N.Y.) and recorded on a digital storage oscilloscope, Tecktronix 2212, (Tektronix Beaverton, Oreg.) and based upon prior instrument calibration is expressed in atmospheres. Core temperature are maintained using a homeothermic blanket available from Harvard Apparatus (South Natick, Mass.). Temperature of the temporalis muscle is continuously monitored using a thermistor probe available from Physiotemp Systems (Clifton, N.J.). Halothane administration is maintained at about 1.0%.
- Arterial blood samples are removed immediately preceding and at about 30 minutes following sham treatments or fluid percussion injuries for analysis of blood gases, electrolytes, pH, lactic acid, and hematocrit. Fluid percussion pressures are about 4.0 to about 5.0 atm, and typically yield moderately severe brain injuries. Cranial luer connectors are disconnected immediately following delivery of the fluid percussion pulse. Sham control rats are handled in an identical manner with the exception of the delivery of the fluid pressure pulse.
- Immediately following fluid percussion injury, post-traumatic hypoxia is induced by substituting a 10% oxygen source to deliver the halothane for continued anesthesia. At the conclusion of about 30 minutes of posttraumatic hypoxia, an arterial blood sample is removed for blood gas analysis. The arterial catheters are then removed and the surgical wound sites are closed with nylon sutures and treated with the topical antibacterial furizolidine. The rats are kept warm with a Vetko thermal barrier until recovered from anesthesia (i.e. ambulatory), at which time they are returned to the operant conditioning chambers or to their home cages. In all experimental groups, at the conclusion of acute monitoring, arterial and venous catheters are removed, the surgical wound sites are closed with nylon sutures and treated with the topical antibacterial furizolidine.
- The dosages of the lipoic acid compounds may be adjusted based on evaluation of initial studies. ALA will be given s.c., as per Wolz & Kriglstein (1996) Neuropharmacology 35:369-375, which is herein incorporated by reference. For example, about 50 mg/kg of ALA and about 25 mg/kg of DHLA is administered s.c. about 30 minutes after FP (immediately after the post-FP hypoxia). Follow-up doses of about 100 mg/kg of ALA and about 50 mg/kg of DHLA may be given s.c. at about 3, about 24, about 48 and about 72 hours after FP.
- About 300 mg/kg of the nitrone, SPBN, is administered s.c. about 30 minutes after FP, with repeated injections s.c. about every four hours for about 72 hours. In studies examining the effects of vitamin E, about 25 mg/kg of alpha-tocopherol, are injected i.p. about 0.5, about 3, about 24, about 48 and about 72 hours after FP. About 50 μg selenium is administered i.p. whenever alpha-tocopherol is administered.
- For studies evaluating prophylactic treatments, about 100 mg/kg of ALA are administered s.c. daily for three days prior to FP, followed by about 50 mg/kg s.c. one hour prior to FP. If ALA is administered only, then about 100 mg/kg of ALA are administered s.c. about 72 hours, about 48 hours, about 24 hours, about 2 hours or a combination thereof prior to FP. If
coenzyme Q 10 is administered, then about 200 mg/kg ofcoenzyme Q 10 is administered p.o.×10 days. If SPBN is administered, about 300 mg/kg is administered s.c. q.i.d. during about 72 hours of pretreatment. If alpha-tocopherol is administered, about 25 mg/kg is injected i.p. about two hours prior to FP. About 50 micrograms i.p. of selenium may be administered when alpha-tocopherol is administered. - Sprague-Dawley rats weighing about 200 g to about 280 g from Charles River (Wilmington, Mass.) are maintained either in hanging cages or housed separately, on 12 hour light-dark cycles with unlimited access to food and water. All procedures are performed with aseptic techniques and sterile instruments and electrodes/cannulae which are autoclaved or glass bead sterilized. Surgical procedures are performed with about 37.5 mg/kg intraperitoneal injection i.p. pentobarbital sodium anesthesia. At the time of complete insensitivity to painful stimuli, e.g. nonresponsive to tail pinch at about 20 minutes post-injection, the scalp is shaved, a surgical scrub is performed, and the rat placed in a stereotaxic frame. For stereotaxic surgery, the incisor bar is set about 3.3 mm below the intraaural line. The skull is exposed and the periosteum removed and the surface of the skull is dried and marked for electrode placement.
- A. Surgical preparation for Intracortical injection of ferric chloride for acute seizures.
- A burr hole is made in a location over the sensorimotor cortex, about 2 mm posterior and lateral to bregma and either 300 mM iron chloride or saline is unilaterally stereotaxically injected intracortically, 2.5 mm ventral to bregma, using a 30 gauge Hamilton syringe over a period of about 2 minutes. After the Hamilton syringe is withdrawn, gelfoam (Gelfoam, Kalamazoo, Mich.) is packed into the burr hole. Extradural cortical recording electrodes are implanted to evaluate the presence or absence of seizure events (rhythmic ictal EEG). Burr holes for the EEG leads, from the transmitter, are drilled in the top of the skull, about 2 mm on either side of the midline and about 2 mm anterior to lambda. The silastic insulation on the EEG leads is removed to reveal about 5 to about 8 coils of the wire. The exposed wire is then turned about 180° in line with the remaining lead and placed sideways into the hole in the skull. The leads are then attached to the implanted electrodes with a lead connector kit or leads are continuous to the transmitter. All electrodes and leads are coated with Teflon™ except for contact points requiring conductance. A cannula may also then be placed in the right lateral ventricle if i.c.v. drug administration is planned. If an i.c.v. cannula is included, an acrylic mount is constructed to hold the cannula in place while dental acrylic is secured over set screws and the electrodes (opening around the electrodes and cannula is closed with gel foam). Otherwise, if no i.c.v. cannula is implanted, the electrode assembly is completely subcutaneous.
- B. Surgical implantation of miniature EEG radio transmitter and connection to electrodes.
- About a 2 cm incision is made in the midscapular area and a pocket under the skin is created with a hemostat so that the subcutaneous opening is large enough to accommodate the transmitter and coiled electrodes. A transmitter is inserted in the opening. A single channel transmitter, such as CTAF40 (Data Sciences International, St. Paul, Minn.), is used for the acute seizure study; a two-channel transmitter, such as TL10M3-F50-EET (Data Sciences International, St. Paul, Minn.), is used for bilateral hippocampal recording electrodes in the amygdalar delayed seizure study. A sterile trocar with sleeve will be used to create a subcutaneous channel opening up to the scalp incision, and, after the trocar is removed, the transmitters are passed through the sleeve to the appropriate burrholes in the skull surface making contact with the dura and then covered with gelfoam. A small acrylic mount is constructed to cover the electrodes and a set screw in the skull for stability of the recording electrodes.
- C. Surgical placement of amygdalar cannula for injection of ferric chloride for induction of delayed, spontaneous clonic seizures.
- Burr holes are made in locations appropriate for stereotaxic coordinates per atlas of Paxinos and Watson, THE RAT BRAIN IN STEREOTAXIC COORDINATES. Academic Press, New York (1986), which is herein incorporated by reference. Coordinates for the amygdaloid body is about 3.3 mm posterior and about 5.0 mm lateral to the bregma and about 8.5 mm below the surface of the skull. A 22 gauge guide cannula, lumen occluded with stylet, is stereotaxically placed about 0.5 mm above the left amygdala. Coordinates for the dorsal hippocampus is about 3.3 mm posterior and about 1.5 mm bilateral to the bregma and about 3.4 mm below the surface of the skull. Teflon-coated stainless steel recording electrodes with less than about 0.25-mm bare tips are positioned into dorsal hippocampi bilaterally in the dorsal hippocampi to evaluate the presence or absence of seizure events (rhythmic ictal EEG). Stainless steel screws are positioned in the occipital bone to provide reference and ground contacts. All electrodes are attached to wires with pin adapters and then affixed to the skull with dental acrylic. Implantation of miniature EEG radiotransmitter, connection to electrodes and post-surgical analgesia are accomplished as described in section B.
- D. Intra-surgical and post-surgical care.
- During surgery and anesthesia recovery, rats are monitored by trained personnel and maintained on heating pads having a temperature of about 37 ° C. to aid in the regulation of body temperature. About 0.25 to about 0.5 mg/100 g of Butorphanol tartrate (Torbugesic™, A. J. Buck. Owings Mills, Md.) is administered s.c. at the onset of surgery and thereafter for the treatment of pain as evidenced by the presence of signs of discomfort such as piloerection, hunched posture, inactivity and/or anorexia. Rats are observed until they are eating, drinking and resting in a natural position after anesthesia. Rats are individually housed in cages over receivers (RPC 1) and allowed free access to food and water and are maintained on a 12 hour/12 hour light/dark cycle.
- E. Intra-amygdalar ferric chloride injections for delayed seizures.
- After about 5 days of recovery the stylet is removed from the guide cannula and replaced with an injection cannula comprising a 24-gauge guide wire, the tip of which is about 0.5-mm length of fused silica (0.075 mm i.d., 0.15 mm o.d.). Freely moving animals are injected with an aqueous solution of about 1.5 μl of about 100 mM ferric chloride (FeCI3) having a pH of about 2.2 at a rate of about 1 μl per minute using a microinfusion pump. Control animals are injected with about 1.5 μl of about 0.9% NaCl, with pH adjusted to about 2.2.
- F. 24 hour EEG and videotape recording.
- EEG determinations are initiated by placing the entire microisolator on top of the Data Sciences International (DSI) Physiotel Receiver Model RPC-1 (St. Paul, Minn.) connected to a Data Exchange Matrix (DSI, St. Paul, Minn.) and a Pentium III 733 Mhz computer using a DSI A.R.T. II System (DSI, St. Paul, Minn.) for Windows NT. EEG is acquired and stored for analysis. The transmitter is activated by swiping a magnet over the subcutaneous implantation site, and EEG recording is initiated by placing the rat over the top of an RPC-1 receiver (DSI, St. Paul, Minn.).
- G. EEG for acute intracortical ferric chloride.
- EEG is recorded only for 24 hours. Examples of epileptiform spike and spike/wave patterns are illustrated in FIGS. 3a and 3 b. Specific parameters for data/statistical analysis include the number of seizure events per unit time, seizure duration or duration of rhythmic paroxysmal activity and overall slowing of electrical activity in and power spectral analysis of EEG. In the power spectral analysis, identification of a decrease in mean frequency values of the amplitude spectrum of equal to or greater than about 0.5 Hz in two or more of the following frequency bands is indicative of meaningful lesions in tested regions: δ(0.5-5 Hz), θ(5-10 Hz), α(10-16 Hz), β(16-48) and total (0-48). Twenty-four hour videotaping of animals will be used to verify behaviors associated with seizures identified by EEG. After about 24 hour EEG, rats are euthanized, perfused and brains removed. The area of cortical lesion is quantified by digital photographic imaging. Brains are then prepared for histological analysis as described above.
- ii. EEG recording in delayed seizure model.
- EEG data is recorded as above on a round-the-clock basis for about 30 days after intra-amygdalar ferric chloride injection. Twenty-four hour videotaping of animals is used to verify behaviors associated with seizures identified by EEG. Behaviors are scored from review of the video images by using the criteria of set forth by Racine, R. (1972) Electroencephalogr. Clin. Neurophysiol. 32:281-294, which is herein incorporated by reference, by an observer blind to the nature of the injectate received by the animals. After about 30 days, rats are tested for memory function in the Morris water maze as described below. After behavioral testing, rats are euthanized, perfused and brains removed, sectioned and stained to ascertain amygdalar placement and identify siderosis.
- H. Assessment of pharmaceutical interventions.
- For selected protective agents or combinations of agents, treatment with ALA is given s.c., as per Wolz & Kriglstein (1996) Neuropharmacology 35:369-375, which is herein incorporated by reference. In the ferric chloride-induced seizure experiments, about 100 mg/kg of ALA and about 50 mg/kg DHLA is administered s.c. about 30 minutes after ferric injection. Follow-up doses of about 100 mg/kg of ALA and about 50 mg/kg of DHLA are given s.c. at about 3, about 24, about 48 and about 72 hours after ferric chloride. About 300 mg/kg of SPBN or 150 mg/kg of PBN is administered s.c. 30 minutes after FP with repeated injections every four hours lasting for about 72 hours. In studies examining the effects of vitamin E, about 25 mg/kg of alpha-tocopherol is injected i.p. about 0.5, about 3, about 24, about 48 and about 72 hours after FP. About 50 μg of selenium is administered i.p. whenever alpha-tocopherol is administered. In all experiments vehicle-treated groups and sham-operated groups are studied which identifies any effects of the compounds tested on EEG or memory. The dosages may be adjusted as necessary.
- For studies evaluating prophylactic treatments, about 100 mg/kg of ALA are administered s.c. daily for three days prior to FP, followed by about 50 mg/kg s.c. one hour prior to FP. If ALA is administered only, then about 100 mg/kg of ALA are administered s.c. about 72 hours, about 48 hours, about 24 hours, about 2 hours or a combination thereof prior to FP. If
coenzyme Q 10 is administered, then about 200 mg/kg ofcoenzyme Q 10 is administered p.o. × 10 days. About 300 mg/kg of SPBN or about 100 mg/kg of PBN is administered s.c. q.i.d. during about 72 hours of pretreatment. If alpha-tocopherol is administered, about 25 mg/kg is injected i.p. about two hours prior to FP. About 50 micrograms i.p. of selenium may be administered when alpha-tocopherol is administered. - These studies are evaluated by multi-way analysis of variance. When a significant F score is found, an a posteriori or a priori test involving a multiple comparison of means, whichever is appropriate, will be used to compare individual treatment groups.
- The Morris water maze is used to evaluate the extent to which fluid percussion injury or amygdalar ferric chloride injection impairs a rat's ability to learn the location of a submerged platform in a pool of water. During the two days that precede sham treatment or fluid percussion injury, the training on the visual recognition memory task is suspended and each rat is trained to swim to the safety of a non-visible submerged platform in a circular pool of water (26 ° C.). On each of these days, a rat will be placed randomly at one of four locations (north, south, east, or west) in a circular pool of water and allowed to swim for about 60 seconds. If during that time the rat locates the submerged platform, it is allowed to remain on the platform for about 10 seconds. But, if the rat fails to locate the platform, at the end of about 60 seconds, it is removed from the pool. 12 learning trials are scheduled/day with about four minute breaks between each learning trial. Similarly, water maze training is accomplished two days prior to surgery for placement of amygdalar ferric chloride cannulae.
- Since injury induced motor impairments might interfere with any retention tests of maze performance, the first water-maze retention test does not occur until the 8th post-injury day. However, daily tests of visual recognition memory are scheduled for the first seven days after fluid percussion injury. On the 8th post-injury day, visual discrimination assessments are discontinued and five retention trials are scheduled. Retention trials are identical in every respect to pre-injury learning trials, including the location of the platform. On the 9th day, the platform is removed and a probe trial is used to determine whether a rat's preference was controlled by location of the platform or by visibility. On days 11-14, the location of the platform is changed on successive test days.
- The rat's performance during all learning and retention tests is tracked and quantified by the TSE VideoMot2 (www.TSE-Systems.de) video tracking system. For each rat, the number of entries into the four quadrants (zones) of the pool, time spent in each zone, distance traveled, swim speed, as well as latency to find the platform from the initiation of a trial is collected for each rat.
- In the visual non-matching-to-sample experiments, rats are housed in individual test cages that contain three levers, a dot-pattern module above each lever, and a food trough below the center lever. Initially, a dot pattern is illuminated over one of the side levers and rats are trained to press the lever beneath the illuminated dot pattern. After rats learn to track the location of the dot pattern above the side levers, one of several dot-patterns is illuminated above the center lever. A press on the center lever will turn the sample pattern off and simultaneously illuminate comparison dot patterns above each of the side levers. The dot pattern above one side lever matches the (sample) pattern and the dot pattern above the other lever is different. A press on the lever beneath the comparison dot pattern that is different from the sample pattern results in the delivery of food and immediately initiates a 10 second inter-trial interval. At the end of the inter-trial interval, one of the seven dot-patterns is randomly selected for presentation as a new sample.
- However, a press on the lever beneath the comparison dot pattern that matches the sample dot pattern ends the trial and after a 10 second inter-trial interval, a correction trial is initiated. The previous sample is represented as a flashing dot pattern and a press on the center lever results in the representation of the comparison stimuli that appeared on the previous trial. On a correction trial, the comparison pattern that matches the flashing sample does not flash and the probability is 0.50 that the previous sample will reappear above the same lever. After a rat's non-matching performance stabilizes, a delay of variable duration will be imposed between presentation of the sample pattern and the presentation of the comparison patterns. Prior to FP, different delays between offset of the sample and presentation of the comparison patterns will be used to determine the extent to which the passage of time or activity within the delay interfere with recall of the sample.
- In all experiments, accuracy and latency data from each day's experimental session will be maintained in computer files. Standard graphic display programs are used to prepare graphs and the data from experimental and control groups are analyzed with a computer program, such as SASr, using repeated measures analysis of variance and appropriate contrast tests to identify significant group differences on recovery days. See Bauman et al., (2000) Journal of Neurotrauma 17(8):679-693, which is herein incorporated by reference.
- After the completion of the functional assessments described above, the rats are anesthetized with about 70 mg/kg of ketamine and about 6 mg/kg of xylazine i.m. After thoracotomy and laceration of the right atrium of the heart, rats are sequentially perfused transcardially with physiological saline which results in euthanasia by exsanguination and about a 10% formalin solution for fixation. Brains are removed and, after additional immersion fixation, paraffin-embedded Nissl-stained tissue sections are prepared.
- In rats subjected to intracortical injection of ferric chloride, the area of cortical lesion are quantified by digital photographic imaging.
- For rats subjected to amygdalar ferric chloride injection, alternate sections are stained with Prussian Blue, to reveal the extent and location of siderosis and cresyl violet stained sections will be examined for cavitation and gliosis in the basolateral amygdala. Placement of dorsal hippocampal electrodes are evaluated in cresyl violet stained sections through that region.
- Sections from FP-injured and sham rats are examined by specifically focusing on anticipated injury-induced changes in neuronal cell numbers within the hilar region of the dentate gyrus of the hippocampus. Normal neurons are identified by he presence of nuclei with clear nucleoplasm, surrounded by cytoplasm containing Nissl substance. Hilar neuronal cell numbers are counted in six 30 micron non-adjacent sections per Lowenstein et al., (1992) J. Neuroscience 12(12):4846-4853, which is herein incorporated by reference, and compared among treatment groups in subsequent statistical analysis. In addition, other neuroanatomical hallmarks of fluid percussion injury, e.g. cortical contusion, hippocampal CA1 and CA3 neurons, may be examined, and if suitably consistent within experimental groups, are analyzed by nonparametric, e.g. blinded rater score or parametric, e.g. cell number analysis. In brains from rats subjected to FP injury, degenerative changes in the lateral geniculate nucleus are determined as reported by Bauman et al. (2000) Journal of Neurotrauma accepted pending revision, which is herein incorporated by reference.
- When the probability of an F score for an overall comparison among groups is p<0.05, Dunnett's test is used for post-hoc comparisons among group means. Cell counts in the hilar region of the dentate gyrus are compared using analysis of variance. Differences among nonparametric histopathological scores are determined by means of the Kruskal-Wallis test.
- The neuroprotective effect of the lipoic acids, such as DHL, may be significantly enhanced by the co-administration of SPBN and PBN.
- A. DHL and SPBN.
- Cultured neurons were incubated with four DHL concentrations, 3.0, 10.0, 30.0, and 100.0 micromolar of DHL, with or without 10 mM SPBN for four hours. After incubation, an oxidative insult was applied by adding 50 micromolar of H2O2 for 30 minutes after which the medium was removed and replaced with Minimum Essential Medium (MEM) (Sigma, St. Louis, Mo.). After 24 hours, the colormetric MTT assay as described above was conduced to determine amount of neuroprotection.
- As shown in Table 1 below and FIG. 5, SPBN significantly increased the neuroprotective efficacy of DHL. The combination of 100 micromolar DHL and 10 mM SPBN provided almost complete protection against H2O2-induced oxidative insult.
TABLE 1 Treatment % DHL uM SPBN mM Neuroprotection n 3 0 1.31 ± 5.23 8 3 10 10.48 ± 3.04 8 10 0 −3.68 ± 5.14 8 10 10 44.51 ± 11.98*** 8 30 0 7.04 ± 7.38 8 30 10 48.64 ± 6.09** 7 100 0 28.48 ± 5.83 8 100 10 86.44 ± 8.44*** 8 - Data are depicted as means ±SEM (n=7 or 8). Significance was determined by one way ANOVA and the differences between the means was assessed by the Tukey-Kramer test. ** p<0.005; *** p<0.001.
- B. DHL and PBN.
- Cultured neurons were incubated with four DHL concentrations, 3.0, 10.0, 30.0, and 100.0 micromolar of DHL, with or without 10 mM PBN for four hours. After incubation, an oxidative insult was applied by adding 50 micromolar of H2O2 for 30 minutes after which the medium was removed and replaced with Minimum Essential Medium (MEM) (Sigma, St. Louis, Mo.). After 24 hours, the colormetric MTT assay as described above was conduced to determine amount of neuroprotection.
- As shown in Table 2 below and FIG. 6, PBN significantly increased the neuroprotective efficacy of DHL.
TABLE 2 Treatment % DHL uM SPBN mM Neuroprotection n 3 0 −1.3 ± 7.2 7 3 10 20.7 ± 10.5 6 10 0 22.2 ± 13.6 8 10 10 56.9 ± 11.6 8 30 0 22.1 ± 9.7 8 30 10 87.4 ± 12.0 8 100 0 36.9 ± 9.6 8 100 10 81.6 ± 11.2 6 - Data are depicted as means ±SEM (n=6, 7, 8). Significance was determined by one way ANOVA and the differences between the means was assessed by the Tukey-Kramer test.** p<0.005; *** p<0.001.
- Incorporation by Reference
- To the extent necessary to understand or complete the disclosure of the present invention, all publications, patents, and patent applications mentioned herein are expressly incorporated by reference to the same extent as though each were individually so incorporated,
Claims (48)
1. A method of treating a subject suffering from a central nervous system injury or disease comprising administering to the subject a composition comprising a therapeutically effective amount of at least one lipoic acid compound.
2. The method of claim 1 , wherein the central nervous system injury or disease is traumatic brain injury, posttraumatic epilepsy, stroke, cerebral ischemia, or a neurodegenerative disease.
3. The method of claim 1 , wherein the central nervous system injury is induced by fluid percussion, a blunt object impacting the head of the subject, an object which penetrates the head of the subject, or exposure to radiation, ionizing or iron plasma, electroconvulsive shock therapy, a nerve agent, cyanide, toxic concentrations of oxygen, central nervous system malaria, or an anti-malaria agent.
4. The method of claim 1 , wherein the subject is a mammal.
5. The method of claim 4 , wherein the mammal is human.
6. The method of claim 1 , wherein the lipoic acid compound is alpha-lipoic acid, dihydrolipoic acid, 2-(N,N-dimethylamine) ethylamido lipoate-HCL, the oxidized or reduced R- or S-isomers thereof, a metabolite of alpha-lipoic acid, or an analog thereof.
7. The method of claim 1 , wherein the composition is alpha-lipoic acid, dihydrolipoic acid, or 2-(N,N-dimethylamine) ethylamido lipoate-HCL.
8. The method of claim 1 , wherein the composition further comprises at least one reactive oxygen species scavenger or at least one neurotrophic factor.
9. The method of claim 8 , wherein the reactive oxygen species scavenger is coenzyme Q, vitamin E, vitamin C, pyruvate, melatonin, niacinamide, N-acetylcysteine, GSH, or a nitrone.
10. The method of claim 1 , wherein the therapeutically effective amount is about 0.001 mg to about 20 mg per kg of the subject.
11. The method of claim 10 , wherein the therapeutically effective amount is about 1 mg to about 10 mg per kg of the subject.
12. The method of claim 11 , wherein the therapeutically effective amount is about 3 mg to about 10 mg per kg of the subject.
13. The method of claim 1 , further comprising a pharmaceutically acceptable excipient.
14. The method of claim 1 , wherein the composition is administered intravenously, intradermally, subcutaneously, orally, transdermally, transmucosally or rectally.
15. The method of claim 14 , wherein the composition is administered intravenously.
16. The method of claim 14 , wherein the composition is administered orally.
17. The method of claim 14 , wherein the composition is administered subcutaneously.
18. A method of preventing or inhibiting a central nervous system injury or disease in a subject comprising administering to the subject a composition comprising a therapeutically effective amount of at least one lipoic acid compound.
19. The method of claim 18 , wherein the central nervous system injury or disease is traumatic brain injury, posttraumatic epilepsy, stroke, cerebral ischemia, or a neurodegenerative disease.
20. The method of claim 18 , wherein the central nervous system injury is induced by fluid percussion, a blunt object impacting the head of the subject, an object which penetrates the head of the subject, or exposure to radiation, ionizing or iron plasma, electroconvulsive shock therapy, a nerve agent, cyanide, toxic concentrations of oxygen. central nervous system malaria, or an anti-malaria agent.
21. The method of claim 18 , wherein the lipoic acid compound is alpha-lipoic acid, dihydrolipoic acid, 2-(N,N-dimethylamine) ethylamido lipoate-HCL, the oxidized or reduced R- or S-isomers thereof, a metabolite of alpha-lipoic acid, or an analog thereof.
22. The method of claim 19 , wherein the lipoic acid compound is alpha-lipoic acid, dihydrolipoic acid, or 2-(N,N-dimethylamine) ethylamido lipoate-HCL.
23. The method of claim 18 , wherein the composition further comprises at least one reactive oxygen species scavenger or at least one neurotrophic factor.
24. The method of claim 23 , wherein the reactive oxygen species scavenger is coenzyme Q, vitamin E, vitamin C, pyruvate, melatonin, niacinamide, N-acetylcysteine, GSH, or a nitrone.
25. The method of claim 18 , wherein the therapeutically effective amount is about 0.001 mg to about 20 mg per kg of the subject.
26. The method of claim 25 , wherein the therapeutically effective amount is about 1 mg to about 10 mg per kg of the subject.
27. The method of claim 26 , wherein the therapeutically effective amount is about 3 mg to about 10 mg per kg of the subject.
28. The method of claim 18 , further comprising a pharmaceutically acceptable excipient.
29. The method of claim 18 , wherein the composition is administered intravenously, intradermally, subcutaneously, orally, transdermally, transmucosally or rectally.
30. The method of claim 29 , wherein the composition is administered intravenously.
31. The method of claim 29 , wherein the composition is administered orally.
32. The method of claim 29 , wherein the composition is administered subcutaneously.
33. A method of preventing, inhibiting or treating a central nervous system injury or disease, neurotoxicity or memory deficit in a subject comprising administering to the subject a composition comprising a therapeutically effective amount of at least one lipoic acid compound.
34. The method of claim 33 , wherein the lipoic acid compound is alpha-lipoic acid, dihydrolipoic acid, 2-(N,N-dimethylamine) ethylamido lipoate-HCL, the oxidized or reduced R- or S-isomers thereof, a metabolite of alpha-lipoic acid, or an analog thereof.
35. The method of claim 33 , wherein the composition further comprises at least one reactive oxygen species scavenger or at least one neurotrophic factor.
36. The method of claim 35 , wherein the reactive oxygen species scavenger is coenzyme Q, vitamin E, vitamin C, pyruvate, melatonin, niacinamide, N-acetylcysteine, GSH, or a nitrone.
37. A pharmaceutical composition for preventing, inhibiting, or treating a central nervous system injury, disease or neurotoxicity in a subject comprising a therapeutically effective amount of at least one lipoic acid compound and a pharmaceutically acceptable excipient.
38. The pharmaceutical composition of claim 37 , wherein the lipoic acid compound is alpha-lipoic acid, dihydrolipoic acid, 2-(N,N-dimethylamine) ethylamido lipoate-HCL, the oxidized or reduced R- or S-isomers thereof, a metabolite of alpha-lipoic acid, or an analog thereof.
39. The pharmaceutical composition of claim 37 , wherein the composition further comprises at least one reactive oxygen species scavenger.
40. The pharmaceutical composition of claim 39 , wherein the reactive oxygen species scavenger is coenzyme Q, vitamin E, vitamin C, pyruvate, melatonin, niacinamide, N-acetylcysteine, GSH, or a nitrone.
41. A kit comprising a composition comprising a therapeutically effective amount of at least one lipoic acid compound.
42. The kit of claim 41 , wherein the lipoic acid compound is alpha-lipoic acid, dihydrolipoic acid, 2-(N,N-dimethylamine) ethylamido lipoate-HCL, the oxidized or reduced R- or S-isomers thereof, a metabolite of alpha-lipoic acid, or an analog thereof.
43. The kit of claim 41 , wherein the kit or the composition further comprises at least one reactive oxygen species scavenger or at least one neurotrophic factor.
44. The kit of claim 42 , wherein the reactive oxygen species scavenger is coenzyme Q, vitamin E, vitamin C, pyruvate, melatonin, niacinamide, N-acetylcysteine, GSH, or a nitrone.
45. The kit of claim 41 , further comprising a device for administrating the composition.
46. The kit of claim 41 , further comprising instructions for use.
47. The method of claim 33 , wherein the lipoic acid compound is administered before the central nervous system injury or disease, neurotoxicity or memory deficit.
48. The method of claim 33 , wherein the lipoic acid compound is administered after the central nervous system injury or disease, neurotoxicity or memory deficit.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/839,905 US6469049B1 (en) | 2000-04-21 | 2001-04-20 | Method of treating, preventing or inhibiting central nervous system injuries and diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19895800P | 2000-04-21 | 2000-04-21 | |
US09/839,905 US6469049B1 (en) | 2000-04-21 | 2001-04-20 | Method of treating, preventing or inhibiting central nervous system injuries and diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
US6469049B1 US6469049B1 (en) | 2002-10-22 |
US20020177558A1 true US20020177558A1 (en) | 2002-11-28 |
Family
ID=26894315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/839,905 Expired - Fee Related US6469049B1 (en) | 2000-04-21 | 2001-04-20 | Method of treating, preventing or inhibiting central nervous system injuries and diseases |
Country Status (1)
Country | Link |
---|---|
US (1) | US6469049B1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1442743A1 (en) * | 2003-01-28 | 2004-08-04 | KeyNeurotek AG | Medicament comprising alpha-lipoic acid, ambroxol and/or inhibitors of the angiotensin converting enzyme (ACE) for use in the treatment of neurodegenerative diseases |
US20090169533A1 (en) * | 2008-01-02 | 2009-07-02 | Marine Bio Co., Ltd. | Compositions and methods for treating neurodegenerative diseases |
WO2011028503A1 (en) * | 2009-08-24 | 2011-03-10 | Hough Ear Institute | Methods for treating acute acoustic trauma |
WO2012115306A1 (en) * | 2011-02-24 | 2012-08-30 | 경상대학교산학협력단 | Composition including vitamin c for protecting fetal nerve cells, and functional health food including same |
US10894098B2 (en) | 2012-04-09 | 2021-01-19 | Signablok, Inc. | Methods and compositions for targeted imaging |
US11097020B2 (en) | 2009-10-09 | 2021-08-24 | Signablok, Inc. | Methods and compositions for targeted delivery |
EP3746393A4 (en) * | 2018-02-02 | 2021-11-03 | Galen Therapeutics Llc | Apparatus and method for protecting neurons and reducing inflammation and scarring |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6890896B1 (en) * | 1999-11-18 | 2005-05-10 | Ceremedix, Inc. | Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
WO2003077900A1 (en) * | 2002-03-14 | 2003-09-25 | Prevention, L.L.C. | A unifying mechanism and methods to prevent cancer and neurodegenerative diseases |
AU2003284101A1 (en) * | 2002-10-10 | 2004-05-04 | Neurorecovery, Inc. | System and method of active neuro-protection for detecting and arresting traumatic brain injury and spinal cord injury |
US7361681B2 (en) * | 2003-03-28 | 2008-04-22 | Sygnis Bioscience Gmbh & Co. Kg | Method of treating amytrophic lateral sclerosis using melatonin |
US20090054513A1 (en) * | 2007-08-22 | 2009-02-26 | Response Scientific, Inc. | Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease |
US7943163B2 (en) | 2007-08-22 | 2011-05-17 | Response Scientific, Inc. | Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes |
ES2643628T3 (en) * | 2009-10-13 | 2017-11-23 | Dsm Ip Assets B.V. | Reduction of the risk of pathological effects of traumatic brain injury |
AU2012218094A1 (en) * | 2011-02-18 | 2013-08-29 | Nestec S.A. | Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals |
WO2015130955A1 (en) | 2014-02-27 | 2015-09-03 | New York University | Minimally invasive subgaleal extra-cranial electroencephalography (eeg) monitoring device |
US11119127B2 (en) | 2017-08-01 | 2021-09-14 | Carlos Moreno | Method and apparatus for non-intrusive program tracing with bandwidth reduction for embedded computing systems |
US11666553B2 (en) | 2020-02-25 | 2023-06-06 | North Cell Pharmceticals Inc. | Method of reducing anxiety in non-human mammals by increasing brain serotonin levels |
WO2024026200A1 (en) * | 2022-07-27 | 2024-02-01 | Redox Bioscience LLC | Methods and compounds for treating ulcerative colitis, systemic lupus erythematosus, sepsis, and post-sepsis syndrome |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0382066A3 (en) * | 1989-02-09 | 1992-01-08 | ASTA Medica Aktiengesellschaft | Use of dihydroliponic acid as an analgetic, antiphlogistic and/or cytoprotective agent |
US5552891A (en) * | 1994-10-31 | 1996-09-03 | International Business Machines Corporation | Automated mask alignment for UV projection expose system |
US5977162A (en) * | 1996-09-16 | 1999-11-02 | Seidman; Michael D. | Therapeutic treatment for auditory function |
US6197340B1 (en) | 1998-05-28 | 2001-03-06 | Medical Research Institute | Controlled release lipoic acid |
US6432434B1 (en) | 1999-04-22 | 2002-08-13 | The United States Of America As Represented By The Secretary Of The Army | Treatment of and/or prophylaxis against brain and spinal cord injury |
US6339102B1 (en) | 1999-06-09 | 2002-01-15 | The United States Of America As Represented By The Secretary Of The Army | Method and composition for treating and preventing retinal damage |
-
2001
- 2001-04-20 US US09/839,905 patent/US6469049B1/en not_active Expired - Fee Related
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040219207A1 (en) * | 2003-01-28 | 2004-11-04 | Peter Rohnert | Drug preparation comprising alpha-lipoic acid, ambroxol and/or inhibitors of the angiotensin-converting enzyme (ACE) and its use for the treatment of neurodegenerative diseases |
US7858655B2 (en) | 2003-01-28 | 2010-12-28 | Keyneurotek Pharmaceuticals Ag | Drug preparation comprising α-lipoic acid, ambroxol and/or inhibitors of the angiotensin-converting enzyme (ACE) and its use for the treatment of neurodegenerative diseases |
EP1442743A1 (en) * | 2003-01-28 | 2004-08-04 | KeyNeurotek AG | Medicament comprising alpha-lipoic acid, ambroxol and/or inhibitors of the angiotensin converting enzyme (ACE) for use in the treatment of neurodegenerative diseases |
US20090169533A1 (en) * | 2008-01-02 | 2009-07-02 | Marine Bio Co., Ltd. | Compositions and methods for treating neurodegenerative diseases |
WO2009088939A3 (en) * | 2008-01-02 | 2009-09-11 | Marine Bio Co., Ltd. | Compositions and methods for treating neurodegenerative diseases |
CN101945653A (en) * | 2008-01-02 | 2011-01-12 | 海洋生物有限公司 | Compositions and methods for treating neurodegenerative diseases |
US8168675B2 (en) | 2008-01-02 | 2012-05-01 | Marin Bio Co., Ltd. | Compositions and methods for treating neurodegenerative diseases |
CN101945653B (en) * | 2008-01-02 | 2013-01-16 | 海洋生物有限公司 | Compositions and methods for treating neurodegenerative diseases |
KR101417201B1 (en) * | 2008-01-02 | 2014-07-08 | 마린 바이오 씨오., 엘티디. | Compositions and methods for treating neurodegenerative diseases |
WO2011028503A1 (en) * | 2009-08-24 | 2011-03-10 | Hough Ear Institute | Methods for treating acute acoustic trauma |
US10555915B2 (en) | 2009-08-24 | 2020-02-11 | Hough Ear Institute | Methods for treating acute acoustic trauma |
US11097020B2 (en) | 2009-10-09 | 2021-08-24 | Signablok, Inc. | Methods and compositions for targeted delivery |
WO2012115306A1 (en) * | 2011-02-24 | 2012-08-30 | 경상대학교산학협력단 | Composition including vitamin c for protecting fetal nerve cells, and functional health food including same |
US10894098B2 (en) | 2012-04-09 | 2021-01-19 | Signablok, Inc. | Methods and compositions for targeted imaging |
EP3746393A4 (en) * | 2018-02-02 | 2021-11-03 | Galen Therapeutics Llc | Apparatus and method for protecting neurons and reducing inflammation and scarring |
US11911504B2 (en) | 2018-02-02 | 2024-02-27 | Galen Therapeutics Llc | Apparatus and method for protecting neurons and reducing inflammation and scarring |
Also Published As
Publication number | Publication date |
---|---|
US6469049B1 (en) | 2002-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6469049B1 (en) | Method of treating, preventing or inhibiting central nervous system injuries and diseases | |
AU710341B2 (en) | Method of treatment of diabetic neuropathy and vascular change or diabetic retinopathy | |
Vorwerk et al. | Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. | |
US6369106B1 (en) | Treatment of ischemic brain injuries with brain targeted anti oxidant compounds | |
US4871774A (en) | Medical treatment | |
US6174875B1 (en) | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke | |
Hebert et al. | Normal and drug-induced locomotor behavior in aging: comparison to evoked DA release and tissue content in Fischer 344 rats | |
CN104487062B (en) | Treatment method for treating Parkinson's | |
JP2008525488A (en) | 1-aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional instability and uncontrollable emotions | |
JP2008260782A (en) | Kit using deprenyl compound to maintain, prevent loss or recover nerve cell function | |
JP2008502705A (en) | Compounds and methods for treating seizures and seizure disorders | |
EP1870097A1 (en) | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | |
CN107106521A (en) | New treatment for treating Parkinson's | |
JP2016074728A (en) | Use of 4-aminopyridine to improve neurocognitive and/or neuropsychiatric impairment in patients with demyelinating and other nervous system disorders | |
WO1999051223A1 (en) | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke | |
Dawson Jr et al. | An age-related decline in striatal taurine is correlated with a loss of dopaminergic markers | |
Philips et al. | In vivo release of endogenous dopamine from rat caudate nucleus by phenylethylamine | |
Meyerhoff et al. | Lipoic acid pretreatment attenuates ferric chloride-induced seizures in the rat | |
WO2001080851A1 (en) | Method of treating, preventing or inhibiting central nervous system injuries and diseases | |
US6525017B1 (en) | Using glutathiane to protect neurons from injury | |
Coert et al. | Exogenous spermine reduces ischemic damage in a model of focal cerebral ischemia in the rat | |
Rinne et al. | Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor | |
US20070191427A1 (en) | Use of n-piperidine derivatives for the treatment of neurodegenerative pathologies | |
SK2902002A3 (en) | Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof | |
BILOBA | 17. IN VIVO STUDIES OF THE PHARMACOLOGICAL AND BIOCHEMICAL ACTIVITIES OF GINKGO BILOBA EXTRACT (EGb 761) AND ITS CONSTITUENTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ARMY, UNITED STATES, MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MEYERHOFF, JAMES L.;YOURICK, DEBRA L.;KOENIG, MICHAEL L.;REEL/FRAME:013049/0013 Effective date: 20011106 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20101022 |